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Introduction: The risk of biofilm formation in orthodontic patients is even higher than 
the general dental population due to the presence of microniches and increased surface 
area provided by orthodontic brackets and appliances. If left untreated, oral biofilm can 
cause white spot lesions, gingivitis and halitosis. Traditional mechanical and chemical 
methods of managing biofilm formation all have limitations, which warrants the search 
for novel ways of biofilm management. Probiotics have shown to be beneficial in the oral 
health of general dental patients. Therefore the aim of this study was to investigate the 
efficacy of the oral probiotic Streptococcus salivarius M18 in managing biofilm 
formation in patients wearing fixed orthodontic appliances and to assess its effects on the 
oral microbiome of these patients. 
 
Methods: The study was designed as a prospective, randomised, triple-blind, two-arm 
parallel-group, placebo-controlled trial. Sixty-four patients undergoing fixed treatment 
consumed 2 lozenges daily of probiotic (n = 32) or placebo (n = 32). The outcome 
measures were plaque index (PI), gingival index (GI) and halitosis-causing volatile 
sulphur compound (VSC) levels. Oral microflora was analysed utilising next-generation 
sequencing of the bacterial 16S rRNA gene. 
 
Results: No significant differences in PI and GI scores were found between probiotic 
group and placebo-control group (p > 0.05). The level of VSCs significantly decreased in 
both probiotic group (VSC reduction = -8.5%, p = 0.015) and placebo group (-6.5%, p = 
0.039) after 1-month. However, after the 3-month follow-up, VSC levels of the placebo-
control group returned to baseline levels whereas those of the probiotic group decreased 
further compared to baseline readings (-10.8%, p = 0.005). The next-generation 
sequencing showed that the oral ecology of both groups was similar and that there was a 
significant increase in the abundance of streptococci in both the probiotic and placebo 
group over time. 
 
Conclusion: Oral probiotic S. salivarius M18 reduced the VSC levels in patients with 
fixed appliances but did not decrease their plaque or gingival indices. The influence of 
probiotic S. salivarius M18 on oral microflora seems to be minimal. A longer intervention 
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Oral biofilms can cause a number of oral diseases such as dental caries, periodontitis, 
gingivitis, halitosis and candidosis. Mechanical and chemical methods have traditionally 
been used to remove oral biofilms but they have limitations. Oral probiotics have shown 
potential in affecting pathogens found in biofilms without impacting negatively on the 
normal oral microbiota and thus their application in dental patients has garnered much 
attention. Probiotics come in a number of strains, all of which have similar mechanisms 
of action exerting their effects on pathogens either directly or indirectly. Their use in 
dental patients has shown a good proportion of positive effects on caries, periodontitis, 
gingivitis, candidosis and halitosis. 
 
The risk of biofilm formation in orthodontic patients is even higher than the general 
dental population due to the presence of microniches and increased surface area 
provided by orthodontic brackets and appliances. For this reason, the effect of probiotics 
on orthodontic biofilms is gaining a lot of interest. There have only been a handful of 
studies investigating the effect of probiotics in orthodontic patients, although the effects 
have been somewhat positive. However, studies to date are difficult to compare and 
often conducted quite poorly. There are a number of obvious gaps in the current 
literature that make comparing studies and drawing accurate conclusions on this subject 
somewhat difficult. Hence this review on probiotics and oral health concludes with 
suggestions of possible future directions probiotic studies should take when tested in 
dental populations. By doing this, it is intended that their true relevance in dentistry and 




Biofilm-related oral diseases, including dental caries and periodontal disease, have 
historically been considered the most important global oral health burdens (Petersen, 
2008). These diseases cause pain, infections and tooth loss, severely impacting on the 
ability to eat, systemic health, self-esteem and quality of life in both children and adults 
(Rosenoer and Sheiham, 1995; Griffin et al., 2012; Jansson et al., 2014; Li et al., 2014). 
In developed countries, oral diseases are the fourth most expensive to treat with an 
estimated 5-10% of public health budgets going towards managing these diseases 
(Quock, 2015). 
 
The significant role of biofilms in oral health and disease is shown in an extensive 
number of epidemiological and clinical studies (Marsh, 2006; Filoche et al., 2010; 
Marsh et al., 2011; Wade, 2013). Poor management of oral hygiene can allow the 
accumulation of oral biofilm in the oral cavity. It is now becoming clear that many 
human illnesses, such as dental caries, periodontal disease and cardiovascular disease, 
are directly or indirectly related to a disruption in the equilibrium of the oral microbiota. 
This has lead to an increased interest in new ways to reduce disease causing microbial 
populations (Zarco et al., 2012). 
 
Mechanical and chemical methods, such as tooth brushing and mouth rinses, have 
been traditionally used to prevent the accumulation of the oral biofilm. Effective manual 
or powered brushing and the use of interdental brushes are still the most important 
measures for oral hygiene control in patients (Brinkmann, 2005; Busscher et al., 2010; 
Kossack and Jost- Schatzle et al., 2010). Manual toothbrushes with a special head 
design, such as staged, v-shaped, or triple-headed, are more efficient than brushes with a 
conventional planar bristle field in patients with difficult to reach areas such as around 
brackets in those undergoing orthodontic treatment (Rafe et al., 2006). Some studies 
have found that powered toothbrushes are superior to manual toothbrushes in removing 
biofilm. However the comparison between different powered toothbrushes is difficult 
because of their different oscillation frequencies, types of vibration, areas or types of 
bristles, and study criteria or methods used in these experiments (Costa et al., 2007; 
Schatzle et al., 2010). Despite the fact that new designs of general toothbrushes come on 
the market regularly, longer brushing time and proper brushing techniques are still 
necessary for good oral hygiene. 
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There are a variety of measures that provide chemical control of oral biofilms. 
Some of these include the incorporation of antimicrobials into toothpastes, mouth rinses, 
varnishes and adhesives. Chlorhexidine still remains the most effective antimicrobial in 
reducing biofilm-induced iatrogenic side effects in patients (Gehlen et al., 2000a; 
Gehlen et al., 2000b). Unfortunately, long-term use of chlorhexidine is known to stain 
teeth and tongue and affect taste sensation (McCoy et al., 2008). The benefits of fluoride 
containing toothpastes and mouth rinses in preventing caries are widely known (Walsh 
et al., 2010). As well as aiding enamel remineralisation, fluoride acts as a buffer to 
neutralize acid-producing bacteria and suppresses their growth (Busscher et al., 2010). 
Stannous fluoride provides dual benefits with respect to caries and biofilm prevention 
by stannous ions (Wiegand et al., 2009). However, these measures of manipulating oral 
biofilms all have their limitations and with increasing bacterial resistance to chemical 
agents, the investigation of novel ways to manage biofilms is warranted (Zero, 2006). 
 
Oral probiotics, which can improve oral health by affecting pathogenic bacteria 
without impacting negatively on the normal oral microbiota, are becoming popular 
(Reid et al., 2011). Probiotics are defined by the World Health Organization as ‘live 
organisms which, when administered in adequate amounts confer a health benefit on the 
host’ (Burton et al., 2013). Probiotics used for oral health present as a number of 
different strains, such as Lactobacillus, Bifidobacterium and Streptococcus (Burton et 
al., 2013). They have shown promise as a novel way to combat dental biofilms and 
strengthen natural micro-flora against pathogens that cause major oral diseases such as 




Historical perspectives on oral probiotics and their mechanisms of action 
 
The use of probiotics to improve oral health is a relatively new concept, however the 
use of probiotics to improve health is not. In the early 20th Century, a Nobel Prize 
laureate, Elie Metchnikoff, reported that Bulgarians lived longer than other populations 
due to their consumption of fermented milk products containing good bacteria 
(Twetman and Stecksen-Blicks, 2008). The suggested mode of action was competition 
with pathogens, resulting in a favourable balance of ‘good’ bacteria to ‘bad’ bacteria 
(Cildir et al., 2009) 
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Most mechanisms of action are aimed at reducing biofilm accumulation and 
antagonising oral pathogens such as Streptococcus mutans and Porphyromonas 
gingivalis. They can be classified as direct or indirect actions. Direct interactions in 
biofilms, include the production of antimicrobial substances (organic acids, hydrogen 
peroxide, bacteriocins), secretion of toxins, enzymes and waste products, competition 
with pathogenic organisms for adhesion sites on mucosa, disruption of the binding of 
oral microorganisms to proteins, and interruption of bacteria to bacteria attachments 
(Meurman, 2005; Bonifait et al., 2009;). The indirect actions in the oral cavity include 
the modification of the surrounding environment by modulating pH and oxidation- 
reduction potential which compromises the ability of pathogens to become established, 
stimulation of nonspecific humoral immunity, modulation of humoral and cellular 
immune responses, regulation of mucosal permeability and allowing the colonisation of 







Traditionally, probiotics have been bacteria of intestinal origin, and their application has 
been in relieving problems of the gastrointestinal tract (Burton et al., 2013). 
Consequently, most studies investigating the potential of probiotics in preventing oral 
diseases have been based on intestinal probiotic strains. Although many strains have 
been investigated over the years, the most commonly used strains for oral health are 
those belonging to the genera Lactobacillus, Bifidobacterium and Streptococcus, such as 
Lactobacillus rhamnosus GG, Lactobacillus reuteri ATCC 55739, Bifidobacterium DN- 
173010 (Saxelin et al., 2005) and Streptococcus salivarius strains K12 and M18 (Burton 
et al., 2006; Burton et al., 2013). To a lesser extent, Weissella cibaria also plays a part 
in oral health, but mainly in the management of halitosis (Bjorkroth et al., 2002). 
Lactobacillus 
 
The ability of Lactobacillus reuteri SD 2112 and Lactobacillus rhamnosus GG to 
influence the colonisation of mutans streptococci has been studied (Haukioja et al., 
2008). L. reuteri exists in the human gastrointestinal tract as an obligatory 
heterofermentative. Its exact mode of action is unclear but a number of suggestions have 
6  
been put forward. Firstly, L. reuteri produces anti-microbial substances called reuterin 
and reutericyclin (Talarico et al., 1988). These substances are water-soluble and broad- 
spectrum antimicrobials. They are effective in a wide range of environments and 
resistant to both proteolytic and lipolytic enzymes (el-Ziney and Debevere, 1998). 
Reuterin inhibits Gram-positive and Gram-negative microorganisms (El-Ziney et al., 
1999). Secondly, L.reuteri strains have the ability to prevent the binding of pathogenic 
bacteria to host tissue. They also promote anti-inflammatory cytokine activity in the 
intestinal mucosa. Another possible mode of action is preventing the adherence of 
pathogenic bacteria and modifying the protein composition of the salivary pellicle 
(Haukioja et al., 2008). 
Weissella cibaria 
 
Weissella cibaria, originally classified in the genus Lactobacillus, is a Gram-positive 
facultative anaerobic lactic acid bacterium (Bjorkroth et al., 2002). W. cibaria secretes 
hydrogen peroxide and a bacteriocin that can act against other bacteria (Kang et al., 
2006; Kang et al., 2006b). It can also coaggregate with Fusobacterium nucleatum and 
adhere to epithelial cells (Kang et al., 2006b). These properties potentially allow W. 
cibaria to colonise the oral cavity and prevent the proliferation of pathogenic bacteria. 
Bifidobacterium 
 
Strains of bifidobacteria exist in the human gastrointestinal tract. They exert similar 
effects to lactobacilli, such as the regulation of microbial homeostasis, the inhibition of 
harmful bacteria that colonise or infect the mucosa and the modulation of local and 
systemic immune responses (Cildir et al., 2009). 
Streptococcus 
 
Probiotic Streptococcus salivarius M18 and Streptococcus salivarius K12, both known 
to produce BLIS (bacteriocin-like inhibitory substances), are relatively new probiotic 
strains. Unlike Lactobacillus and Bifidobacterium probiotic strains, these two S. 
salivarius probiotic strains are sourced from the human oral cavity itself (Burton et al., 
2013). They belong to commensal species that are known to have low pathogenic 
potential and were claimed to be the world’s first probiotics developed specifically for 
the mouth and throat (Burton et al., 2013). 
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S. salivarius probiotic strains (M18 and K12) have the potential to offer oral health 
benefits through the production of bacteriocins (Burton et al., 2013). These bacteriocins 
are antimicrobials, synthesised by ribosomes and have a narrow inhibitory spectrum 
against similar bacteria (Wescombe et al., 2009). The main difference between K12 and 
M18 is their inhibitory spectrum. K12 is mainly inhibitory towards S. pyogenes and 
upper respiratory tract pathogens (due to the production of salivaricin A and B); while 
M18 is less active on some of the upper respiratory tract pathogens but has strong 
activity against dental pathogens, in particular Streptococcus mutans (presumably due  
to the production of the bacteriocins salivaricins M, 9 and A) (Wescombe et al., 2009). 
 
As well as producing bacteriocins that target the main decay causing species, 
S.mutans, these strains produce enzymes dextranase and urease, which have the 
potential to further limit the progression of dental caries by reducing dental plaque 
accumulation and acid levels in the mouth (Burton et al., 2013; Nascimento et al., 
2009). They also work by competing with pathogenic organisms for adhesion sites and 




Clinical applications of oral probiotics 
 
Oral probiotics has been extensively studied and clinically used to reduce biofilm 
formation, inhibit pathogenic microorganisms, and prevent biofilm-related diseases such 
as dental caries, gingivitis, periodontitis, candidosis and halitosis (Meurman, 2005; 
Twetman and Stecksen-Blicks, 2008; Stamatova and Meurman, 2009; Teughels et al., 




Dental caries is still the most prevalent chronic disease worldwide, despite technological 
advancements and new initiatives introduced by the dental profession. The caries 
disease process is triggered by the interaction of cariogenic microorganisms, such as 
mutans streptococci and lactobacilli, a diet high in fermentable carbohydrates and host 
factors such as saliva secretion rate and buffering capacity (Selwitz et al., 2007). 
Currently, the most commonly used and recommended products to combat caries are 
toothbrushes,  floss,  antimicrobial  toothpastes  and  mouth  rinses.  Treatments    using 
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conventional anti-streptococcal antimicrobials appear to be effective in reducing dental 
biofilm formation and levels of mutans streptococci in the short-term (Burton et al., 
2013). However, their broad-spectrum antimicrobial activity destroys both commensal 
and harmful bacteria, which creates imbalances within the microflora. Antimicrobials 
are also often unpalatable to young children, which can result in poor compliance and 
compromise their intended effect (Burton et al., 2013). 
 
Oral probiotics, on the other hand, have shown to be effective in managing 
cariogenic pathogens without impacting negatively on the normal oral microbiota. Many 
studies have assessed the effect of probiotics on the incidence of caries as well as the 
related main pathogenic microorganisms, such as mutans streptococci and lactobacilli. 
 
Research designs vary greatly, with only a limited number of randomised controlled 
trials and cross-over studies on this subject present. The majority of these studies have 
examined the effect of certain probiotic strains on surrogate measures for caries 
incidence, such as S. mutans levels. For obvious ethical and budget reasons, only a 
handful of studies have examined caries as an outcome measure. However, one has to 
question the value of studies that publish microbiological data over caries incidence as 
there is concern regarding the validity of using S. mutans levels as an indicator of caries 
alone. This is mainly due to the discovery that caries can occur independently of S. 
mutans (Griffen et al., 2011; Gross et al., 2012). 
 
Nevertheless, although there are limitations with assessing surrogate measures for 
caries in the form of S. mutans levels, this review will focus on publications reporting 
probiotic effects on both caries as an outcome measure as well as on levels of caries 
surrogates such as S. mutans. This is mainly due to the majority of quality studies 
investigating probiotic effects on S. mutans levels. To date, as at July 2016, close to 100 
papers can be found in the literature examining the effect of probiotics on caries causing 
microorganisms, such as S. mutans, and on caries incidence. 
Effect of probiotics on caries incidence 
 
Currently, six randomised double-blind controlled trials demonstrate effects of 
probiotics, in which caries incidence is an outcome measure. Out of these, one study is 
on adult populations (Petersson et al., 2011), whereas the other five have investigated 
caries experience in children (Nase et al., 2001; Stecksen-Blicks et al., 2009; Taipale 
et al., 2013; Hasslof et al., 2013; Stensson et al., 2014). Of these, three studies reported
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a beneficial effect of probiotics on childhood caries incidence (Nase et al., 2001; 
Stecksen-Blicks et al., 2009; Stensson et al., 2014) whereas two found that probiotics 
conferred no beneficial effect (Hasslof et al., 2013; Taipale et al., 2013). 
Evidence for a positive effect of probiotics on caries 
 
Lactobacillus rhamnosus and Lactobacillus reuteri strains have been shown to reduce 
the incidence of caries (Nase et al., 2001; Steckson-Blicks et al 2009; Stensson et al 
2014; Petersson et al 2014), however effects on salivary levels of S. mutans have been 
unremarkable (Steckson-Blicks et al 2009; Petersson et al 2014; Stensson et al 2014). 
The popular method of probiotic delivery in these population groups has been milk, 
possibly due to its ease of delivery in these subjects (Nase et al., 2001; Steckson-Blicks 
et al 2009; Petersson et al 2014), however equally positive results have been shown by 
probiotic delivery through oil drops (Stensson et al 2014). 
 
Evidence against a positive effect of probiotics on caries 
 
In contrast, two randomised, controlled trials in the literature show conflicting results to 
those above. This is possibly attributed to different probiotic strains used in these 
studies. 
Lactobacillus paracasei F19 consumed in cereal form showed little difference in 
caries rates or S. mutans levels between the probiotic and control group (Hasslof et al., 
2013). Similarly Bifidobacterium animalis subsp. lactis BB-12 taken in tablet form 
showed little difference in caries experience (Taipale et al., 2013). However, this study 
was limited in that it did not compare the probiotic to a placebo but rather control 
groups taking either xylitol or sorbitol. Conclusions on the true effect of probiotics on 
caries incidence therefore cannot be drawn, as sorbitol and xylitol groups were taking 
anti-cariogenic agents in their own right. 
Reasons for differences in the findings 
 
Studies on the effect of probiotics on caries incidence are difficult to compare due to the 
variety of study conditions such as: 
 
Sample size-These vary greatly between studies. 
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Probiotic strain – Each study varies in its choice and concentration of probiotic 
strain. Some strains may be more effective in different areas of the body and in different 
doses and this may also translate to the mouth. 
 
Age of populations – Studies vary in their selection of target populations. Different 
maturity in immune systems can influence microbial populations and should be taken 
into consideration when comparing ages of population groups. 
 
Mode of delivery – There are a huge variation in the way of administering 
probiotics. These include oil, milk, lozenges, yoghurt and gum, to name a few. This may 
affect the concentration of probiotics that are administered or indeed how well they stay 
or are absorbed at their site of action. 
Microbiological methods – Most studies estimate levels of S. mutans with culture- 
based methods that have limitations. Additionally, their accuracy and reliability over 
molecular methods using genetic analysis to identify the bacterial species present, is 
somewhat questionable. 
 
Study duration – Study durations vary for weeks to months, which have obvious 
influences on outcome measures and persistence and concentration of intra-oral 
microbes. 
Effect of probiotics on S. mutans 
 
For obvious ethical and budgeting reasons, the majority of studies investigating the 
effects of probiotics use measures of S. mutans levels as an indicator of potential caries 
experience. Additionally, S. mutans levels allow researchers to speedily obtain 
significant microbiological changes (e.g. weeks) compared to the time required for 
clinical changes to occur (e.g. months or years). 
 
To date, a combination of 15 relatively well designed randomised controlled trials 
and cross-over studies, all of which are included in a recent meta-analysis (Laleman et 
al., 2014b), showed that probiotics reduce the levels of S. mutans. Interestingly, type of 
probiotic strain administered, mode of delivery or length of time did not seem to have 
an effect on results. 
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Major conclusions from previous studies 
 
Probiotic  strains  L.  reuteri  (especially  L.  reuteri  ATCC  55730)  and  L. rhamnosus 
(especially L. rhamnosus GG) have a caries prevention effect in children. 
Probiotics reduce levels of S. mutans. This may indicate that probiotics can 
influence the composition of the oral micro-ecology community and offer protection 
from pathogenic microorganism induced dental conditions such as caries, halitosis, 
gingivitis, periodontitis and candidosis. 
Periodontitis 
 
The main pathogens associated with periodontitis are P. gingivalis, Treponema 
denticola, Tannerella forsythia and Aggregatibacter actinomycetemcomitans (Ishikawa 
et al., 2003). These bacteria can colonise subgingivally, escape the host’s defense 
system and  cause tissue damage (Ishikawa et al., 2003). 
 
Traditional mechanical and chemical methods of managing biofilms that cause 
periodontitis have their limitations. Some biofilms are difficult to disrupt by mechanical 
means, especially when they are subgingival or protected by tooth anatomy or 
restorations and some bacteria within these biofilms are resistant to certain chemical 
assaults (Darby, 2009). Probiotics have been shown to improve plaque and gingival 
indices, probing depths and bleeding on probing in subjects with gingivitis and 
periodontitis (Riccia et al., 2007; Kang et al., 2006a; Krasse et al., 2006). This has been 
demonstrated by a reduction in total anaerobic bacteria, especially the number of black- 
pigmented anaerobic rods, P.gingivalis and Campylobacter rectus (Teughels et al., 
2011; Ishikawa et al., 2003). Additionally, probiotics like Lactobacillus reuteri have 
shown to exert positive treatment effects by promoting anti-inflammatory cytokine 
activity as it does in the intestinal mucosa (Krasse et al., 2006) and L. brevis has also 
demonstrated an anti-inflammatory mechanism of action through the prevention of 
nitric oxide production, the release of PGE2 and the activation of MMPs (Riccia et al., 
2007). Furthermore, probiotics have been found to offer a long-term benefit to patients 





The elderly are often susceptible to oral candidosis, either due to prolonged antibiotic 
exposure or to accumulated deficiencies in their immune system. Probiotics could 
encourage faster C. albicans clearance (Elahi et al., 2005) and decrease yeast levels in 
patients (Hatakka et al., 2007). Similarly Streptococcus salivarius K12 has indicated a 
direct influence on Candida associated disease progression in mouse studies, that bodes 
well for its possible clinical application in human subjects (Burton et al., 2011). 
Halitosis 
 
Halitosis has many causes, including consumption of particular foods, metabolic 
disorders and respiratory tract infections; but in most cases is associated with an 
imbalance of the commensal microflora of the oral cavity (Scully and Greenman, 2008). 
The anaerobic bacteria in the mouth, such as Porphyromonas gingivalis, can break 
down salivary and food proteins and produce amino acids, which are then transformed 
into volatile sulphur compounds (VSCs), contributing to halitosis (Kang et al., 2006b). 
 
A number of strategies have been used for the prevention of halitosis. For example, 
anti-bacterial toothpaste and mouth rinses are used to reduce the numbers of bacteria, or 
certain odour neutralising or masking agents are used (Scully and Greenman, 2008). 
However, they usually need to be used several times daily and provide only a short-term 
benefit (Scully and Greenman, 2008). 
 
Probiotics provide a new treatment modality for halitosis by introducing a 
beneficial bacterial population to help counter the colonisation and multiplication of the 
odour causing microbes (Kang et al., 2006b). Weissela cibaria has been shown to 
prevent the production of volatile sulphur compounds by Fusobacterium nucleatum, 
possibly because the production of hydrogen peroxide by W. cibaria can prevent the 
proliferation of F. nucleatum (Kang et al., 2006b). Oral probiotic S. salivarius has also 
been found to decrease the VSC levels in the mouth and has shown potential in the 
prevention and treatment of halitosis by combating odour-causing, proteolytic anaerobes 
(Burton et al., 2005). 
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Application in orthodontics 
 
The risk of biofilm formation in orthodontic patients is even higher than in the general 
population because micro niches and increased surface areas provided by orthodontic 
brackets and appliances not only promote biofilm formation but also impede daily oral 
hygiene. 
 
The use of oral probiotics in orthodontic patients may be beneficial since they have 
shown effectiveness in managing caries and decreasing S. mutans level. However, little 
research has been done on the role probiotics can play in orthodontic patients. To date, 
there have only been five studies that have investigated the effect of probiotics in 
patients with fixed appliances (Cildir et al., 2009; Jose et al., 2013; Pinto et al., 2013; 
Ritthagol et al., 2013; Gizani et al., 2015). 
 
Lactobacillus paracasei SD1 (Ritthagol et al., 2013), Bifidobacterium animalis 
subsp. lactis DN-173010 (Cildir et al., 2009) and a probiotic of unknown strain and 
concentration (Jose et al., 2013) have been shown to significantly decrease levels of 
mutans streptococci when delivered in milk, yoghurt, curd and toothpaste respectively. 
Only two of these five orthodontic studies have used the same strain. The strain used 
was Bifidobacterium but each study had different results (Pinto et al., 2013; Cildir et al., 
2009). The first study found that there was a reduction in salivary mutans streptococci in 
orthodontic patients consuming Bifidobacterium animalis subsp. lactis DN-173010 
yoghurt daily (Cildir et al., 2009). On the other hand, the second study found no change 
(Pinto et al., 2013). However the differing results, even though the two studies had 
similar designs and sample sizes, could be attributed to the yoghurt itself, which may 
influence the cariogenic potential and colonisation of the oral cavity (Pinto et al., 2013). 
 
Since previous research on probiotics in dental patients has shown that over time 
Bifidobacterium has less consistent outcomes compared to L. reuteri and L. 
rhamanosus, their further investigation, along with the yet to be tested Streptococcus 
probiotic strains, is warranted in an orthodontic population. 
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Gaps in the current literature 
 
Research on the effect of probiotics on oral health has become increasingly popular, and 
the number of systematic reviews on this topic has significantly increased (Meurman, 
2005; Twetman and Stecksen- Blicks, 2008; Stamatova and Meurman, 2009; Teughels 
et al., 2011; Cagetti et al., 2013; Laleman et al., 2014a; Laleman et al., 2014b; Gruner et 
al., 2016). However, it is acknowledged that in order to gain a better understanding of 
the exact benefits of oral probiotics and draw accurate conclusions, studies need a 
variety of improvements such as: 
 
Gold standard microbial profiling. Analysing the microbial profiles of the biofilm 
with molecular techniques such as by direct PCR-based amplification of the 16S 
ribosomal RNA gene, followed by sequencing of the PCR products using next- 
generation DNA sequencing (e.g. Ion Torrent or Illumina) technology. This method has 
the ability to provide a ‘gold standard’ for bacterial identification, identify known 
species and possibly identify microorganisms that cannot be cultured. It will equally 
provide evidence for the validity of using S. mutans as a surrogate measure for caries 
incidence. 
 
Longitudinal and long-term follow-up studies. Longer observations would allow 
one to analyse the influence of probiotics on the oral micro-ecology at different time 
points and allow for the collection of data on clinical problems such as caries that take 
considerable time to develop. Long-term follow-up can provide information about the 
lasting effects of probiotics after administration has stopped, especially in orthodontic 
patients who usually receive several years of treatment. In addition, long-term studies 
provide the ability to assess whether permanent colonisation of the probiotic has 
occurred, thereby offering protective effects from bacterial induced consequences, 
without the need for continual probiotic consumption. 
 
Administration and concentration of probiotics. Although probiotics administered 
by different modes of delivery have largely shown beneficial results, comparisons of the 
efficacy of delivery methods, such as yoghurt, milk, chewing-gum and lozenges are 
important. Equally, ideal concentrations of the probiotics and their relative substantivity 
would be worthwhile to assess their true benefits when present in the mouth at optimal 
concentrations. 
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Oral probiotic strains. The probiotic strains used in studies vary greatly from centre 
to centre, for example, S. salivarius K12 and M18 are commonly used in New Zealand, 
and they are the only probiotics that have been developed from the mouth, for the 
mouth. In European countries, the majority of research uses L. reuteri, L. rhamnosus 
and Bifidobacterium species (Nase et al., 2001; Nikawa et al., 2004; Caglar et al., 2005). 
Well-designed, high-powered studies allowing one to assess and compare the efficacy 
of these different probiotic strains on oral health are needed in order to find the most 
effective strain for use in dental and orthodontic patients. 
 
Oral probiotics for orthodontic patients. Despite the increasing number of reports 
on the positive effects of oral probiotics decreasing S. mutans levels and preventing 
caries in the general dental population, studies in patients with orthodontic fixed 
appliances are still limited. Considering orthodontic patients are at an increased risk of 
caries, studies on the application of probiotics in orthodontic patients could provide an 
alternative way to combat white spot lesions, gingivitis and halitosis caused by biofilm 




Conclusions and future directions 
 
Probiotic use in oral health is gaining popularity due to the emergence of antibiotic- 
resistant bacteria and the limitations presented by current oral hygiene methods and 
products. The most commonly used probiotic strains for oral health research include 
Lactobacillus, Bifidobacterium and Streptococcus. These strains possess similar 
mechanisms of action that ultimately aim to promote healthy bacteria over bacteria 
prevalent in dental disease. 
 
The effect of oral probiotics on managing dental biofilm formation and its 
consequences, such as caries, periodontal disease, candidosis and halitosis, seems 
encouraging. The probiotic approach to reducing biofilm accumulation makes good 
biological sense, provided the organisms can be delivered often enough to establish their 
presence over their commensal counterparts and offer patients a new beneficial oral 
micro-ecology (Burton et al., 2013). A commonly reported uncertain aspect of probiotic 
use is whether (and for how long) probiotic species are able to colonise the oral 
environment, especially since it is well known that probiotics in the gastrointestinal tract 
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usually colonise for a short time only (Rao et al., 2012). There are a number of 
publications that indicate long-term colonisation can occur after probiotic consumption 
ceases, although this is only seen in select participants. 
 
It is therefore necessary for future studies to investigate why some probiotics 
colonise select patient’s mouths even after administration ceases, whereas in others, 
beneficial effects of probiotics are only received as long as the probiotics are being 
administered. Additionally, since there are many strains of probiotics on the market, it 
will be useful to investigate which probiotic strains can colonise the oral cavity most 
effectively and offer long-term oral health benefits. It has also been noted that the way 
in which probiotics are delivered can affect their success, yet few studies have 
compared modes of delivery. It is worthwhile investigating this area further to ascertain 
whether the effects seen by the probiotics are aided by their mode of delivery or strictly 
due to their individual mechanisms of action. 
Overall, it seems that although probiotics have been known for their benefits in 
health, their application in oral health is still very much in its infancy and well 
conducted studies with long term follow up are scarce. Therefore, well-designed 
randomised controlled trials (RCTs), the ‘gold standard’ for evaluating the effectiveness 
of interventions (Akobeng, 2005), are needed to provide further scientific clinical 
evidence on this promising, yet poorly understood topic (Cagetti et al., 2013). Success  
in orthodontic patients could provide an alternative regime to limit the deleterious 
effects of biofilm accumulation, such as gingivitis, white spot lesions and halitosis. 
 
 
Aims of this thesis 
 
The aims of this thesis are to investigate the efficacy of oral probiotic Streptococcus 
salivarius M18 in managing biofilm formation in patients wearing fixed orthodontic 




To determine if oral probiotic S. Salivarius M18 is effective in: 
1. Reducing biofilm formation  
2. Establishing a balance between ‘good’ and ‘bad’ bacteria  
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Efficacy of oral probiotic Streptococcus salivarius M18 in 
enhancing oral hygiene in patients wearing fixed  appliances 




Introduction: Orthodontic fixed appliances promote biofilm formation, leading to clinical 
problems such as enamel demineralisation, gingivitis and halitosis. Oral probiotics show 
promise in managing biofilms in general dental patients, but the efficacy of oral probiotics in 
enhancing oral hygiene in patients with fixed orthodontic appliances is still unclear. 
Materials and Methods: The study was designed as a prospective, randomised, triple-blind, 
two-arm parallel-group, placebo-controlled trial with a 1-month treatment intervention and a 
3-month treatment-free follow-up. A total of 64 patients undergoing orthodontic treatment at 
the Faculty of Dentistry, University of Otago, Dunedin, New Zealand, were selected for the 
study. Those eligible were 10 to 30 years of age, with at least 20 natural teeth, wearing 
stainless steel brackets, and using fluoride toothpaste not containing any supplementary 
antibacterial agents for daily oral hygiene. Participants were randomly assigned to two groups 
based on computer-generated random sequencing using balanced block randomization. In the 
oral probiotic group (n = 32), the patients consumed two probiotic lozenges containing the 
probiotic Streptococcus salivarius M18 each day for 1-month; in the placebo-control group 
(n = 32), the patients consumed two placebo-control lozenges without probiotic each day. 
The patients, investigators and statistician were blinded to the patient allocation, and the 
researcher managing the random sequence did not participate in allocation or measurement. 
At each appointment (baseline, 1-month, 4-month), plaque index (PI) and gingival index (GI) 
scores were recorded. Volatile sulphur compounds (VSCs) levels were measured using a 
Halimeter. Results: Compared with the placebo-control group, the probiotics did not 
influence PI or GI scores (interaction time × treatment; p > 0.05). VSC levels decreased 
significantly in the probiotic group (VSC reduction = 17 ppb, p = 0.015) and control group 
(VSC reduction = 13 ppb, p = 0.039) after 1-month treatment. However, after the 3-month 
treatment-free follow-up, the VSC levels of the control group returned to a level (VSC = 203 
± 59 ppb) that was similar to the baseline (VSC = 204 ± 69 ppb) (p = 0.619), whereas the 
VSC levels of the probiotic group reduced further (VSC = 180 ± 47 ppb) and were 
significantly lower (p=0.005) than the baseline (VSC = 201 ± 71 ppb). No side effects were 
observed during the trial. Conclusions: Oral probiotic S. salivarius M18 reduced VSC levels 




The placement of fixed orthodontic appliances can severely impedes tooth brushing and 
provide areas of low salivary flow that promote dental biofilm (plaque) formation (Ren et al., 
2014). Additionally, metabolites such as acids produced by biofilms cannot be effectively 
buffered and removed by saliva due to the placement of orthodontic appliances (Øgaard, 
2008). If patients fail to maintain good oral hygiene during orthodontic treatment, the biofilm 
formed can cause a number of adverse events, including enamel demineralisation and 
gingival inflammation (Peng et al., 2014). These adverse events can occur in just a few weeks 
after the placement of fixed appliances, severely affecting the treatment results and patient’s 
quality of life (Øgaard, 2008). 
 
Halitosis, more commonly known as bad breath, affects up to half the adult human 
population to various degrees (Yaegaki and Coil, 2000). Although generally not considered  
to be a medical concern, it can certainly confer a significant social stigma (Rosenberg, 2002). 
Fixed orthodontic appliances have been found to significantly increase the plaque and tongue 
coating indices. A positive association between halitosis and the use of fixed orthodontic 
appliances has been confirmed and halitosis has been considered an important indicator of 
oral health during orthodontic treatment (Zurfluh et al., 2013). The volatile sulphur 
compounds (VSCs) produced by oral biofilms, especially anaerobes located on the dorsum of 
the tongue, are considered to be one of the most common contributors to halitosis (Loesche 
and Kazor, 2002) and bacteria such as Leptotrichia and Prevotella are regarded as the main 
halitosis pathogens (Yang et al., 2013). However, no obvious association exists between oral 
malodour and any specific bacterial infection, suggesting that halitosis reflects complex 
interactions between several oral bacterial species (Porter and Scully, 2006) 
 
The measures adopted to prevent and control biofilm formation in orthodontics usually 
include oral hygiene instruction, application of fluoride, (Benson et al., 2004), use of 
antimicrobial dentifrices, mouth rinses (Chen et al., 2011), and antimicrobial modifications of 
orthodontic materials (Shah et al., 2011). Antibiotics can decrease oral bacterial adhesion, 
however, their use can unbalance the normal oral microflora and lead to dysbacteriosis and 
drug resistance (Kouidhi et al., 2011). Although the prevention of biofilm formation in 
orthodontics has been studied extensively, and a variety of dental products for managing oral 
biofilms are commercially available, the prevalence of biofilm-related adverse events during 
orthodontic  treatment,  such  as  enamel  demineralisation,  still  remain  as  high  as   72.9% 
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(Richter et al., 2011). The need for safe and efficacious management of biofilms is of great 
importance, especially in patients with fixed orthodontic appliances. 
 
Probiotics, which are defined by the World Health Organisation as ‘live organisms which, 
when administered in adequate amounts confer a health benefit on the host’, have been  
shown to be effective in various approaches for biofilm management. These include reducing 
dental biofilm formation, preventing caries development and decreasing oral malodor 
(halitosis) (Rao et al., 2012; Saha et al., 2012; Cagetti et al., 2013). Traditionally, probiotics 
have been widely used to improve gut health. Probiotic mechanisms of action usually include 
competing with pathogenic organisms for adhesion sites, secreting antimicrobial substances 
such as bacteriocins and modulating the host’s immune response (Saha et al., 2012; Singh et 
al., 2013). During the last decade, an increasing number of products containing probiotics 
have entered the oral health market and show promise in the prevention and treatment of 
biofilm-related oral diseases (Haukioja, 2010; Gutkowski, 2013). According to recent studies, 
oral probiotics can be an effective and safe therapy for reducing dental biofilms and caries 
risk in children (Juneja and Kakade, 2012; Cannon et al., 2013; Burton et al., 2013a). In 
addition, the oral probiotic Streptococcus salivarius has been found to decrease the VSC 
levels in the mouth and has shown potential in the prevention and treatment of halitosis 
(Burton et al., 2005). Clinical research has confirmed the use of oral probiotic S.salivarius 
M18 as an effective measure in the treatment of dental decay and gingival inflammation 
without negatively impacting the normal oral microflora (Rastall et al., 2005; Burton et al., 
2013a; Burton et al., 2013b). The effect of oral probiotics on managing dental biofilm 
formation seems encouraging and promising. 
 
However, to date, there are few randomised controlled trials (RCTs), the ‘gold standard’ 
for evaluating the effectiveness of interventions (Akobeng, 2005), examining the efficacy of 
oral probiotics in enhancing oral hygiene; even fewer have investigated the role probiotics 
can play in orthodontic patients (Cagetti et al., 2013). To date, five RCTs have examined the 
effect of probiotics on orthodontic patients (Cildir et al., 2009; Jose et al., 2013; Pinto et al., 
2013; Ritthagol et al., 2013; Gizani et al., 2015). However none of these have tested 
probiotic effect on halitosis or used S. salivarius M18. This oral probiotic strain is unique in 
that it has been isolated from the mouth, not the GI tract like others. . 
 
The aim of this trial was to determine the efficacy of oral probiotic Streptococcus 
salivarius M18 in enhancing oral hygiene in patients wearing fixed orthodontic appliances. 
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We aimed to assess clinical parameters including Plaque Index (PI), Gingival Index (GI), and 








The study was designed as a prospective, randomised, triple-blind, two-arm parallel-group, 
placebo-controlled trial with a 1-month treatment intervention and a 3-month treatment-free 
follow-up. Data were collected between July 2015 and December 2015. An oral examination 
was taken at baseline, then after 1 and 4 months (Figure 2.1). The study examiners, 
orthodontic patients, and statisticians were blinded to the treatments given. The study was 
approved by the University of Otago Ethics Committee (H14/103) as well as the local Maori 
Research Consultation Committee. The trial was registered with the Australian New Zealand 
Clinical Trials Registry (ANZCTR) (ACTRN12615000341527). 
Participants 
 
A total of 64 orthodontic patients at the Faculty of Dentistry, University of Otago, Dunedin, 
New Zealand, (age range, 10-30 years) wearing fixed appliances were recruited into the 
study. The determination of sample size was based on previous estimates of plaque index (PI) 
variability (SD, 0.4) in adolescents requiring orthodontic treatment by setting type I error   at 
0.05 and type II error at 0.20 (80% power) (Acharya et al., 2011; Peng et al., 2014). We 
assumed that participants were treated with oral probiotics and found that about 27 patients 
(i.e. a total of 54 for 2 groups) were needed to detect a decrease in the PI of about 30%. To 
allow for possible dropout during the study, we aimed to recruit 64 patients (Figure 2.1, 





































Inclusion and exclusion criteria 
 
Inclusion criteria were having at least 20 natural teeth; and, wearing stainless steel brackets 
(Victory Series; 3M Unitek, Monrovia, California, USA) in both arches. 
 
Exclusion criteria were the presence of systemic disease (e.g. diabetes); living in a non- 
fluoridated area (e.g. Allanton, Waikouaiti and Mosgiel); periodontal disease; antibiotic 
therapy; wearing lingual braces; using a toothpaste with supplementary antibacterial agents; 
using a non-fluoride toothpaste; dental fluorosis; smoking; using powered toothbrushes; 
lactose intolerance; allergy to dairy products; and participants being physically unable to 
brush. 
Randomisation and allocation concealment 
 
Balanced block randomisation (with a block size of four and by blocking on sex) was used to 
ensure equal patient allocation to each treatment group. Allocation concealment was used to 
avoid selection bias and was conducted by a member of the research team (MF). The 
computer-generated random numbers were provided in opaque, sealed envelopes (MF) before 
the intervention was commenced (GB). The patients, investigators and statistician were all 
blinded to the allocation. BLIS Technologies only revealed the identities of the treatment 
groups to the investigators once the intention-to-treat (ITT) analysis was performed. 
Probiotic intervention and placebo-control 
 
Oral probiotic group: participants consumed two lozenges of BLIS M18 S. salivarius (live 
active) bacteria (BLIS Technologies Ltd, Dunedin, New Zealand) each day during the 1- 
month intervention. The dose administered was 3.6 x 109 S. salivarius colony forming   units 
(CFUs)/lozenge. Isomalt (sugar substitute), tableting aids and peppermint flavouring made up 
the rest of the lozenge. 
 
Placebo-control group: participants consumed two placebo-control lozenges (BLIS 
Technologies Ltd, Dunedin, New Zealand) each day during the 1-month intervention. The 
packaging, appearance and taste of lozenges in both intervention and control groups were 
identical. Twenty milligrams of extra isomalt was used in place of the probiotic in the 
placebo-control lozenges. 
 
The manufacturer did not reveal the identities of the treatment groups to the investigators 
until  the  intention-to-treat  (ITT)  analysis  and  statistical  analyses  were  completed.    The 
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participants were informed not to use any other probiotic-containing products during the 
study. 
 
Treatment protocol and follow up 
 
At the baseline appointment, an oral examination was conducted and both PI and GI were 
assessed. Participants were then asked to chew a plaque-disclosing tablet (Disclotabs, 
Colgate-Palmolive, Sydney, New South Wales, Australia) until dissolved and thoroughly 
remove the disclosed dental biofilm by brushing with a new toothbrush (Colgate® Ortho, 
Colgate-Palmolive, Sydney, New South Wales) and toothpaste (Colgate® Cavity Protection 
Toothpaste, Colgate-Palmolive, Sydney, New South Wales, Australia) under the supervision 
of an investigator (GB). The participants then rinsed their mouths with 30 ml chlorhexidine 
mouthwash (Savacol®, Colgate-Palmolive, Sydney, New South Wales, Australia) and water. 
They were then asked to suck the appropriate lozenge. A pack of the lozenges, toothpaste, 
toothbrush, compliance Lozenge Reminder Chart, pen and further instructions were given to 
the participants to take home. Each participant provided at least one email address and mobile 
telephone number to which morning and night email and text message reminders were 
regularly sent throughout the entire 1-month intervention period, to enhance compliance with 
taking the lozenges. 
 
The protocol required the participants to suck two lozenges each day, one after brushing 
their teeth in the morning and one after brushing their teeth at night. The duration of the study 
was 4 months in total, including a 1-month treatment intervention followed by a 3-month 
treatment-free follow-up to assess recurrence rates. 
Study assessments 
 
The modified Plaque Index (PI) (Clerehugh et al., 1998) was used to assess the amount of 
biofilm formation on teeth. This PI system allows for the impact of brackets on biofilm 
distribution and has greater categorical discrimination than the original Silness and Löe index 
(Clerehugh et al., 1998). In this PI scoring system, the teeth were divided into mesial, distal, 
gingival, and incisal (occlusal) regions in relation to the bracket. Plaque was then scored for 
each of the four areas based on four plaque index codes as used by Löe, 1967. The four 
values were averaged for each tooth to give a mean PI tooth score. An overall final mean PI 
for all involved teeth was calculated for each participant. 
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Gingival Index (GI) was measured using a periodontal probe. Four areas around each 
tooth (mesial (labial/buccal), distal (labial/buccal), labial/buccal and lingual/palatal) were 
scored based on four gingival index codes as used by Löe, 1967. A tooth GI mean and a 
participant GI mean was calculated as described above for scoring PI. 
 
Levels of volatile sulphur compounds (VSCs) were assessed in patients’ breath samples 
using a Halimeter (Interscan Corp., Chatsworth, USA) based on the average of three thirty 
second readings recorded as parts per billion (ppb) sulphide equivalents. The peak ppb  
values were displayed at the end of each sample period, as well as an average peak ppb value 
for all three samples. There was a three minute re-calibration period before each sample was 
taken. All of the measurements were performed in a standardised manner following the 
manufacturer’s instructions. 
 
Side effects and patient compliance were also assessed. All remaining lozenges and 
Lozenge Reminder Charts were collected for the analysis of compliance with lozenge 
consumption. No harm to the participants was anticipated, however they were given clear 
directions on their information sheet on how to alert us if any adverse events did occur, so the 
study could be terminated immediately, if necessary. 
Statistical Analysis 
 
An intention-to-treat analysis was carried out using mixed-models and, where appropriate, 
nonparametric Kruskal-Wallis analyses was performed. Statistical analyses were performed 
using SPSS for Mac (version 20.0, IBM Corporation, Chicago, Illinois, USA). Alpha error 
was set at 0.05. The mixed model response variables were “PI”, “GI” and “VSC”. “Sex”, 
“treatment group” and “time” were entered as fixed factors. Due to data clustering within 
participants, the term “patient” was entered as a random term. Where appropriate, Bonferroni 
corrected post-hoc multiple comparisons were run. The efficacy of treatment interventions 




A total of 188 patients were enrolled and assessed for eligibility and 64 recruited for 
randomisation (oral probiotic group n=32 and placebo-control group n=32) (Figure 2.1). 
After the 4-month follow-up, no participants were lost to the study and all participant data 
were included for analysis. No adverse events were recorded during the trial. 
 
The baseline characteristics of the participants are summarised in Table 2.1. Age and sex 




Table 2.1. Baseline characteristics of participants in the two treatment groups. 
 




Age (N, %)   
<14 years 14 (22%) 22 (34%) 
≥14 years 18 (28%) 10 (16%) 
 
Sex (N, %) 
  
Male 12 (19%) 11 (17%) 
Female 20 (31%) 21 (33%) 
Plaque Index (mean ± SD) 1.1 ± 0.4 1.1 ± 0.2 
Gingival Index (mean ± SD) 0.8 ± 0.4 0.8 ± 0.3 
VSCs (ppm) (mean ± SD) 204 ± 69 201 ± 85 
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Plaque Index and Gingival Index 
 
PI scores were not significantly influenced by gender (F=0.2; p=0.685), nor by treatment 
group (F=0.3; p=0.569), or by time (F=1.6; p=0.201). There was no significant interaction 
between treatment group and time (F=1.0; p =0.353) indicating that PI scores did not differ 
between the probiotic and placebo-control group over time (Figure 2.2A). 
 
GI scores were not significantly influenced by gender (F = 0.6; p = 0.455), nor by 
treatment group (F = 0.3; p = 0.867). The interaction between treatment group and time was 








































VSC levels scores were not significantly influenced by gender (F=0.3; p=0.561) and 
treatment group (F=0.2; p=0.619), but they changed significantly over time (F=7.9; p=0.001). 
 
There was a significant interaction between treatment group and time (F=6.4; p=0.01), 
indicating that the changes of VSC over time differed between treatment groups. 
 
Indeed, the level of VSCs decreased significantly in the probiotic group (VSC  reduction 
= 17 ppb, p = 0.015) and placebo-control group (VSC reduction = 13 ppb, p = 0.039) after 
1-month of treatment. However, 3-months after the 1-month intervention, the VSC levels of 
the placebo-control group returned to a level (VSC = 203 ± 59 ppb) that was similar to 
baseline (VSC = 204 ± 69 ppb) (p = 0.619), whereas the VSC levels of the probiotic group 
decreased even more (VSC = 180 ± 47 ppb) compared with the baseline readings (VSC = 201 









This trial assessed the efficacy of oral probiotic S. salivarius M18 at managing biofilm- 
related problems in patients with fixed orthodontic appliances by investigating changes in 
clinical parameters (gingival index (GI), plaque index (PI), volatile sulphur compounds 
(VSCs)). PI scores did not differ between the probiotic and placebo-control groups over time. 
GI scores were also not significantly different between probiotic and placebo-control groups, 
however with time, the GI of both groups worsened. 
 
With regard to VSC levels, there was a significantly decrease in both probiotic group and 
placebo-control group after 1-month of treatment. However, 3-months after the 1-month 
intervention, the VSC levels of the placebo-control group returned to a level similar to 
baseline, whereas the VSC levels of the probiotic group decreased further when compared to 
baseline readings. 
 
This study had several strengths, including a randomised placebo-controlled trial, triple 
blinded, adequate sample size of 64 patients, zero drop-outs, and objective assessment of 
plaque, gingivitis and halitosis. Additionally the compliance with taking the lozenges was 
good. This may have been helped by the provision of a Lozenge Reminder Chart, as well as 
daily email and text message reminders (Paterson et al., 2016). This study was adequately 
powered so the lack of effect from the probiotic on the GI and PI is unlikely to be due to the 
lack of power. 
 
This study had a number of limitations. The most notable is that the 1-month intervention 
was relatively short, which could have contributed to the lack of a positive effect of S. 
salivarius M18 on the PI and GI. The relatively short follow-up period (3 months) was also a 
shortcoming as this time period may have been too short to see a significant change in PI and 
GI scores (Teughels et al., 2008). 
 
The traditional PI and GI indices were initially designed for normal patients without 
fixed orthodontic appliances (Löe, 1967). The modified PI and GI that were used in this study 
accounted for the presence of brackets, making it more fitting for assessing an orthodontic 
population (Clerehugh et al., 1998). Still, PI and GI are somewhat subjective measures and 
difficult to compare between studies. 
 
Operating a Halimeter also has limitations, despite its regular use to measure VSC levels 
in  other  studies  (Rosenberg,  1996;  Salako  and  Philip,  2011).  The  Halimeter cannot 
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discriminate among the sulphur gases, and its sensitivity is relatively lower for methyl 
mercaptan than for hydrogen sulfide. To minimise any potential influence on the VSC 
measurements, we instructed our participants not to eat prior to their visit, as per the 
manufacturer’s guidelines, and performed the measurements at a similar time of the day 
(Shaw, n.d). Although the Halimeter lacks ideal accuracy, it still provides useful data when 
regularly calibrated (Furne et al., 2002). The issue remains with how to interpret the VSC 
readings and discriminate when a reduction can be deemed clinically significant. 
 
To our knowledge, this is the sixth study to assess probiotic effects on the biofilm of 
patients with fixed orthodontic appliances. Previous studies (Cildir et al., 2009; Jose et al., 
2013; Pinto et al., 2013; Ritthagol et al., 2013; Gizani et al., 2015), mainly focused on the 
effect of probiotics on levels of mutans streptococci and lactobacilli, with only one recently 
published long-term RCT (17-month mean intervention), having investigated clinical 
parameters (Gizani et al., 2015), Our study differs from others in that PI, GI and VSC levels 
were assessed. It seems that this is the first time that probiotic effect on VSC levels have 
been evaluated, and the first time probiotic S.salivarius M18 has been tested in an 
orthodontic population. S. salivarius M18 was the probiotic of choice, as it has strong 
activity against dental pathogens, in particular cariogenic S. mutans  (due to the production 
of salivaricins M, 9 and A) (Wescombe et al., 2009). Other commonly used strains for oral 
health include those from the genera Lactobacillus, Bifidobacterium and Streptococcus, such 
as L. rhamnosus GG, L. reuteri ATCC55739, Bifidobacterium DN-173010, but these are all 
derived from the gastrointestinal tract (Saxelin et al., 2005; Cagetti et al., 2013; Laleman et 
al., 2014; Gruner et al., 2016). 
 
When compared with general dental patients, orthodontic patients have a higher risk of 
caries and biofilm formation, due to the impact of fixed orthodontic appliances on oral 
hygiene (Ogaard, 1989; Sudjalim et al., 2007), therefore comparable studies to this one, 
should include an orthodontic population. However due to the scarcity of probiotic studies on 
orthodontic patients and the different study designs and output measures, meaningful 
comparisons are not possible. Like this study, only Gizani and colleagues have assessed 
clinical parameters, namely incidence of white spot lesions. With findings that there was no 
difference in WSL incidence over time, their conclusion that probiotics had little effect in 
adolescent orthodontic patients, was similar to ours (Gizani et al., 2015). Although using non- 
orthodontic dental populations, the influence of oral probiotics on PI and GI was compared in 
a recent systematic review and meta-analysis (Gruner et al., 2016). Similarly, this group 
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found that overall there were no significant reductions in PI, but they did find that there was a 
small yet significant benefit of probiotic therapy on GI. 
 
The mean level of VSCs in patients with fixed orthodontic appliances has been found to 
be significantly higher than the normal population, possibly due to the poorer oral hygiene 
caused by braces (Ogaard, 1989; Sudjalim et al., 2007). The effects on halitosis in 
orthodontic patients have not been investigated before this study. However in a general dental 
population, S. salivarius K12 has been shown to reduce VSC levels in 85% of participants 
when delivered by lozenge (Burton et al., 2006). Besides S. salivarius strains, Weissela 
cibaria has been found to produce similar effects on VSC levels (Kang et al., 2006). 
 
Generally the literature on the effects of probiotics on PI and GI in the general dental 
population shows more significant benefits in patients experiencing oral disease, such as 
gingivitis. Since GI is a marker of inflammation, the more likely effect of probiotics on 
gingival disease could be their effect on host responses rather than on oral pathogens at 
disease sites (Yanine et al., 2013). 
 
A pretreatment using antimicrobial mouth rinse such as chlorhexidine before the 
consumption of oral probiotics was used in this study. We deemed it beneficial to have a 
pretreatment mouth rinse to rid the mouth of its bacterial load thereby allowing the ‘good’ 
probiotic bacteria to dominate the oral microbial community after administration (Aminabadi 
et al., 2011). The lasting effect of chlorhexidine on the oral microbiota should be minimal, 
thereby allowing microbial populations to recolonise to pretreatment levels within 24 hours 
(Rindom Schiøtt et al., 1970). However, the composition of the biofilm post-mouth rinse 
could have been affected by the chlorhexidine thereby influencing the PI, GI and VSCs. It is 
likely, early colonising bacteria would have dominated the mouth though the 1-month 
intervention due to the clear scaffold provided by the rinse. In contrast, a mixture of both 
early and late colonisers in a more mature biofilm are likely to have been present at the 
baseline and 4-month time points. Nevertheless, as both probiotic and placebo-control groups 
received the mouth rinse, the choice to use a pre-treatment shouldn’t have confounded results 
between the groups. 
The influence of the chlorhexidine pre-treatment (Roldan et al., 2004) on the biofilm 
composition or the Hawthorne Effect (McCambridge et al., 2014), may have contributed to 
the control group also having a decrease in the VSC levels after 1-month placebo treatment. 
At commencement of the study, the participants of the placebo-control group and the oral 
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probiotic group were blinded to their treatment and informed that their oral hyene would be 
examined during the trial, therefore, if they paid more attention to their oral hygiene during 
this period, aware that they were being observed, the results could have been influenced 
further. After the 3-month treatment-free follow-up, the VSC levels in the control group 
returned to baseline levels, which may suggest that the microflora had returned to its original 
state. In contrast, the oral probiotic group continued to see a decline in the VSC levels. This 
could be suggestive of S. salivarius M18 possibly colonising the mouth, thereby establishing 
a new and less pathogenic oral micro-ecology, that produced lower levels of VSCs (Burton et 
al., 2013a). 
 
There have been extensive experimental studies and review articles on the use of 
probiotics in general dental patients (Meurman, 2005; Twetman and Stecksen-Blicks, 2008; 
Stamatova and Meurman, 2009; Teughels et al., 2011; Cagetti et al., 2013; Laleman et al., 
2014; Gruner et al., 2016). Although probiotics have been shown to provide benefits in 
general health, their application in oral health, especially orthodontic patients, is still very 
much up for debate as well-conducted comparable studies are limited. In general, there is 
great variation in probiotic strains used, concentrations, dosages, administering methods, 
intervention times, methods for the analysis of bacteria, and different age and makeup of the 
study populations. This makes comparisons of findings difficult. 
 
Considering orthodontic treatment duration is usually about two years, oral probiotics 
could be used as a supplemental practice but not as a substitution for a preventive dental 
program, which includes the use of fluoride, hygiene regimes and regular dental visits. Future 
well-designed randomised controlled trials with long-term follow-up are needed. Although 
ethically questionable, clinical outputs such as white spot lesion incidence or gingivitis would 
be more beneficial that the subjective and difficult to compare assessments of the past, such 
as GI and PI. Additionally, studies utilising molecular techniques such as microbiological 
gene sequencing, are needed for a better understanding of the detailed changes in the oral 




Oral probiotic S. salivarius M18 could reduce VSC levels in patients with fixed appliances 
but did not decrease their plaque index or gingival index. However studies of much longer 
duration are needed to more accurately assess probiotic benefits. Although the reductions in 
VSC levels were statistically significant, the clinical significance of these reductions needs to 
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Oral microbiome changes with use of oral  probiotic 




Placement of fixed appliances in orthodontic patients can promote the formation of 
dental biofilms. Biofilms can lead to problems such as tooth demineralisation, 
gingivitis and halitosis. Commercially available dental products to prevent biofilm 
buildup appear to have little effect. Probiotics show promise in inhibiting biofilm 
growth in general dental patients, but little probiotic research has been carried out 
with the orthodontic population. 
 
In this randomised, triple-blind, placebo-controlled trial, we tested the hypothesis 
that regular consumption of the oral probiotic Streptococcus salivarius M18, by 
patients wearing fixed appliances, will reduce the proportion of pathogenic bacteria in 
an individual’s biofilm. Sixty-four patients aged 12-30 years, undergoing fixed 
orthodontic treatment, consumed two lozenges daily, of either probiotic (n=32) or 
placebo (n=32) for a 1-month period. 
 
We investigated the changes to the orthodontic patient’s oral ecosystem after 
probiotic or placebo lozenge consumption, by utilising next-generation sequencing of 
the bacterial 16S rRNA genes amplified from oral plaque samples. 
 
The effects of the probiotic on the microbial composition were minor, suggesting 
that short-term probiotic use may not be effective in reducing the prevalence of 
potentially pathogenic microbiota in biofilms of orthodontic patients. However, the 
true clinical significance of these effects still deserves further long-term research with 





Orthodontic treatment can improve aesthetics and dental function. The placement of 
fixed orthodontic appliances, however, severely impedes tooth brushing and provide 
areas of low salivary flow that promote dental biofilm (plaque) formation. 
Additionally, metabolites produced by biofilms (such as acids) cannot be effectively 
buffered and removed by saliva due to the placement of orthodontic appliances 
(Øgaard, 2008). If patients fail to maintain good oral hygiene during orthodontic 
treatment, the biofilm formed can cause many adverse events, including enamel 
demineralization and gingival inflammation (Peng et al., 2014). These adverse events 
can occur within just a few weeks after the placement of fixed appliances, severely 
affecting treatment results and the patient’s quality of life (Øgaard, 2008). 
 
Halitosis, more commonly known as bad breath, affects up to half the adult 
human population to various degrees (Yaegaki and Coil, 2000). Although generally 
not considered to be a medical concern, it certainly can confer a significant social 
stigma (Rosenberg, 2002). Fixed orthodontic appliances have been found to increase 
the plaque and tongue-coating indices significantly. A positive correlation between 
halitosis and the wearing of fixed orthodontic appliances has been confirmed and 
halitosis has been considered an important indicator of oral health during orthodontic 
treatment (Zurfluh et al., 2013). Some of the most common contributors to halitosis 
are the volatile sulphur compounds (VSCs) produced by anaerobic bacteria located on 
the dorsum of the tongue (Loesche and Kazor, 2002). Bacteria such as 
Porphyromonas gingivalis and other members of the phylum Bacteroidetes are 
regarded as the main producers of VSCs (Yang et al., 2013). 
 
The measures adopted to prevent and control biofilm formation in orthodontics 
usually include oral hygiene instruction, application of fluoride (Benson et al., 2004), 
the use of antimicrobial dentifrices and mouth rinses (Chen et al., 2011), and 
antimicrobial modifications of orthodontic materials (Shah et al., 2011). Whilst 
antibiotics show effectiveness in decreasing oral bacterial adhesion, their use could 
lead to an imbalance of the normal oral microflora, leading to dysbiosis and drug 
resistance (Kouidhi et al., 2011). Although the prevention of biofilm formation in 
orthodontics has been studied extensively, and a variety of dental products are 
commercially  available,  the  prevalence  of  biofilm-related  adverse  events  such as 
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enamel demineralization still remain as high as 72.9% (Richter et al., 2011). The need 
for safe and efficacious management of biofilms is of great importance, especially in 
patients wearing fixed orthodontic appliances. 
 
Probiotics, which are defined by the World Health Organization as ‘live 
organisms which, when administered in adequate amounts, confer a health benefit on 
the host’ (Burton et al., 2013a) have been shown to be effective in various approaches 
to biofilm management. These include reducing dental biofilm formation, preventing 
caries development and decreasing oral malodor (halitosis) (Rao et al., 2012; Saha et 
al., 2012; Cagetti et al., 2013). Traditionally, probiotics have been widely used for gut 
health. Probiotic mechanisms of action usually include competing with pathogenic 
organisms for adhesion sites, secreting antimicrobial substances (e.g. antimicrobial 
peptides or bacteriocins) and modulating the host’s immune response (Saha et al., 
2012; Singh et al., 2013). During the last decade, an increasing number of products 
containing probiotic organisms have entered the market for oral health purposes and 
show promise in the prevention and treatment of biofilm-related oral diseases 
(Haukioja, 2010; Gutkowski, 2013). According to recent studies, oral probiotics can 
be an effective and safe therapy option for reducing dental biofilm and caries risk in 
children (Juneja and Kakade, 2012; Cannon et al., 2013; Burton et al., 2013a). It is 
important to note that the most effective oral probiotics should ideally be derived  
from oral inhabitants rather than microbes of intestinal origin (Wescombe et al., 2012). 
Several orally-derived probiotic products exist in the market today with a variety of 
claims including reduction of malodor. For example, the commercially-available oral 
probiotic Streptococcus salivarius strain K12 was found to decrease the VSC levels in 
the mouth and showed potential in the prevention and treatment of halitosis (Burton et 
al., 2005). Clinical research has confirmed the use of another oral probiotic strain S. 
salivarius M18 as an effective measure in the treatment of dental decay and gingival 
inflammation without negative impact on the normal oral microflora (Rastall et al., 
2005; Burton et al., 2013a; Burton et al., 2013b). 
 
Although many bacterial strains have been investigated over the years, the most 
commonly used strains for improving oral health are those belonging to the genera 
Lactobacillus, Bifidobacterium and Streptococcus, such as Lactobacillus rhamnosus 
GG, Lactobacillus reuteri ATCC 55739, Bifidobacterium DN-173010 (Saxelin et al., 
2005) and S. salivarius strains K12 and M18 (Burton et al., 2013a). To a lesser extent, 
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Weissella cibaria also plays a part in oral health, but mainly in halitosis management 
(Bjorkroth et al., 2002). There have only been a few clinical studies that have found 
probiotic strains or products to be efficacious in the treatment of halitosis, with the 
most studied including S. salivarius K12 and W. cibaria (Burton et al., 2006; Kang et 
al., 2006). 
 
S. salivarius K12 is known to produce two lantibiotic bacteriocins (salivaricins A 
and B) that are inhibitory to strains of several species of Gram-positive bacteria 
implicated in halitosis. The main difference between strains K12 and M18 is their 
inhibitory spectrum. K12 is mainly inhibitory towards Streptococcus pyogenes and 
upper respiratory tract pathogens (due to the production of salivaricins A and B) while 
M18 is less active on some of the upper respiratory tract pathogens but has strong 
activity against dental pathogens, in particular Streptococcus mutans (due to the 
production of salivaricins A, 9 and M) (Wescombe et al., 2009). Therefore, S. 
salivarius M18 would be an appropriate probiotic strain to assess with regard to any 
beneficial effects on the microbiome of orthodontic patients. 
 
However, to date, randomised controlled trials (RCTs), the ‘gold standard’ for 
evaluating the effectiveness of interventions (Akobeng, 2005) have not been carried 
out in sufficient numbers to provide convincing scientific clinical evidence on the 
efficacy of oral probiotics in enhancing oral hygiene (Cagetti et al., 2013). Even less 
is known of the role probiotics can play in orthodontic patients. To date, only five 
RCTs have examined the effect of probiotics on orthodontic patients (Cildir et al., 
2009; Jose et al., 2013; Pinto et al., 2013; Ritthagol et al., 2013; Gizani et al., 2015). 
 
The study of the biofilm composition in orthodontic patients itself is scarce, with 
the majority of studies having investigated the changes in the microbiome of patients 
by using culture-based or targeted molecular methods (Choi et al., 2009; Thornberg 
et al., 2009; Kim et al., 2012; Torlakovic et al., 2013). These methods are limited by 
the variety of pathogenic species they can detect and so the composition of a typical 
orthodontic patient’s microbiome is still largely unknown. Only recently have 
researchers attempted to address this gap in the literature, with studies using open- 
ended molecular methods to investigate the dynamics of the oral microbiome of 
adolescents during orthodontic treatment (Tanner et al., 2012; Koopman et al., 2015). 
Using   next-generation, namely   Ion   Torrent   (semiconductor), DNA sequencing 
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technology to sequence 16S rRNA genes amplified from oral samples, not only 
enables identification of known bacterial species but also the identification of as yet 
unculturable microorganisms. 
 
In the present study, the aim was to conduct a prospective, randomised, triple- 
blind, two-arm parallel-group, placebo-controlled study, in order to: (i) investigate if 
any changes to the oral microbiota are introduced by probiotic lozenges containing S. 
salivarius M18; and (ii) to determine if the regular consumption of these probiotics is 
effective in reducing biofilm formation, establishing a favourable balance between 
‘good’ commensal bacteria and ‘bad’ potentially pathogenic bacteria in patients 








Orthodontic patients aged 10-30 years wearing fixed appliances at the Faculty of 
Dentistry, University of Otago, New Zealand, were assessed for eligibility by the 
principal investigator G.B. 
 
The inclusion criteria for this study were: at least 20 natural teeth (extraction and 
non extraction patients), wearing conventional stainless steel brackets (3M Unitek) in 
both arches, using fluoride toothpaste not containing any supplementary antibacterial 
agents for daily oral hygiene. The exclusion criteria were: the presence of systemic 
disease (i.e. diabetes), living in a non-fluoridated area (e.g. Allanton, Waikouaiti and 
Mosgiel), periodontal disease, antibiotic therapy or prophylaxis, wearing lingual 
braces, using a toothpaste with supplementary antibacterial agents (e.g. triclosan), 
using a non-fluoride toothpaste, dental fluorosis, smoking, using powered 
toothbrushes, lactose intolerance, allergy to dairy products, and participants being 
physically unable to brush their teeth. 
 
Eligible participants were informed of the study design through an information 
sheet and a total of 64 participants gave their written informed consent. The study 
protocol was approved by the University of Otago Ethics Committee (approval 
number H14/103) as well as the Maori Research Consultation Committee. The trial 
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was accepted for inclusion in the Australian New Zealand Clinical Trials Registry 
(ANZCTR; trial no. ACTRN12615000341527). Whilst no harm to the participants 
was anticipated, they were given clear instructions on their information sheet on how 
to alert the research team if any adverse events did occur so that their participation in 
the study could be terminated immediately, if necessary. 
Sample size 
 
Calculation of the sample size and statistical power were based on previous 
randomised, controlled trials. Type I error was set at 0.05 and type II error at 0.20 
(80% power). At least 27 patients in each group (i.e. a total of 54 for two groups) 
were needed to detect a decrease in biofilm formation of about 30%. To account for 
possible withdrawals during the study, the decision was made to recruit a total of 64 
patients (32 per group). 
Provision of the probiotic-containing product 
 
Lozenges containing Streptococcus salivarius M18 were provided by BLIS 
Technologies Ltd, Dunedin, New Zealand, and were manufactured to contain more 
than one billion viable colony-forming units (CFU) per lozenge at time of 
manufacture. BLIS Technologies has determined that an efficacious dose consists   of 
at least 1 × 108 (100 million) CFU and states that their probiotic is stable enough to 
achieve this with one lozenge even at the end of the stipulated shelf life. 
 
Study protocol and intervention 
 
This prospective, randomised, triple-blind, two-arm parallel-group, placebo-controlled 
study was carried out between July 2015 and December 2015. Figure 3.1 shows the 
flowchart of the clinical trial. 
 
Each participant was randomly allocated to the probiotic group or the control 
group, according to a computer-generated balanced block randomisation method, to 
ensure equal patient allocation to each treatment group. A block size of four was used, 
and it was stratified according to gender. Allocation concealment was used to avoid 
selection bias. Researcher M.F., who managed the random sequence, did not 
participate in the allocation and measurement. The dental investigators, orthodontic 
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patients, laboratory assistants and statisticians were all blinded to the treatments 
given. 
 
The duration of the study was 4 months in total, which included a 1-month 
treatment intervention followed by a 3-month treatment-free follow-up to assess 
recurrence rates. Plaque samples were taken from the participant’s mouths at baseline 
(before treatment), and after one and four months post-treatment. 
 
During the 1-month intervention, the participants in the probiotic group (n=32) 
consumed two probiotic lozenges containing probiotic strain, S. salivarius M18 (BLIS 
Technologies Ltd, Dunedin, New Zealand) daily. The participants in the placebo 
group (n=32) consumed two control (bacteria-free) lozenges daily. For blinding 
purposes, the packaging, appearance and taste of both lozenges was identical. The 
manufacturer did not reveal the identities of the treatment groups to the investigators 
until the intention-to-treat (ITT) analysis was performed. The use of other probiotic- 
containing products during the study was forbidden. 
Clinical Examination 
 
Plaque samples were collected by a researcher (G.B) at all time points (baseline, 1- 
month and 4-months post-treatment). Using sterilized dental probes, supragingival 
dental plaque samples were collected and pooled from buccal/labial/palatal and 
buccal/labial/lingual surfaces of all teeth mesial to, and including, the first molars in 
both upper and lower arches. The samples were transferred to a centrifuge tube 
containing 400 µL of Digestion Buffer (25 mM Tris-HCl, pH 8.0, 2.5 mM EDTA and 
1% [vol/vol] Triton X-100)) and temporarily stored on ice within 30 minutes of 
sampling. Samples were then stored at -80°C until ready for isolation and purification 
of DNA (Appendix 14 and 18). 
 
At the baseline appointment, following the collection of plaque samples, 
participants were asked to chew a plaque-disclosing tablet (Disclotabs, Colgate- 
Palmolive, Sydney, New South Wales, Australia) and then thoroughly remove the 
disclosed dental biofilm in their mouths by brushing with a new toothbrush (Colgate® 
Ortho,  Colgate-Palmolive,  Sydney,  New  South  Wales)  and   toothpaste   
(Colgate® Cavity Protection Toothpaste, Colgate-Palmolive, Sydney, New South 
Wales, Australia) under the supervision of an investigator (GB). The participants then 
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rinsed their mouths with water and a 30-mL cup of chlorhexidine-containing 
mouthwash (Savacol®, Colgate-Palmolive, Sydney, New South Wales, Australia). 
They were then asked to suck the appropriate lozenge. A take-home pack  comprising 
the appropriate lozenges, toothpaste, toothbrush, compliance lozenge reminder chart, 
pen and further instructions were given for home use. The protocol required the 
participants to suck two lozenges each day, one after brushing their teeth in the 
morning and one after brushing their teeth at night for 1 month. 
 
Each participant provided at least one e-mail address and mobile telephone 
number where morning and night email and text message reminders were sent to 
enhance compliance with taking the lozenges. At the 1-month time point, plaque 
samples were collected in a similar manner. In addition, all remaining lozenges and 
Lozenge Reminder Charts were collected for the analysis of compliance with lozenge 
consumption. At the 4-month time point (3-months post-intervention), plaque samples 








































Bacterial DNA extraction and purification 
 
DNA was extracted and purified from the supragingival plaque samples using 
PureLink Genomic DNA Mini Kits (ThermoFisher Life Technologies) in two separate 
batches. Each batch contained 65 samples prepared for an Illumina Miseq sequencing 
run (64 samples and 1 control). The first batch were baseline samples and the second 
batch represented samples taken at the end of the 1-month intervention. Although 
samples were taken at the 4-month time point, these were not prepared for sequencing 
due to funding constraints. (Appendix 15 and 16). 
 
The genomic DNA was quantified spectrophotometrically (NanoVue, GE 
Healthcare) and its quality assessed (by agarose gel electrophoresis on 1-2% [w/v] 
agarose gels) prior to sending the samples for library preparation. 
 
Each sample, which contained at least 20 ng of purified genomic DNA at a 
concentration of at least 5 ng/µl was aliquoted into one of two discrete ABI Fast 96- 
well real-time polymerase chain reaction (PCR) plates, sealed, and packaged in dry 
ice. The first plate contained the baseline samples and the second plate,contained the 
1-month post-treatment genomic DNA samples. Both plates were then sent for next- 
generation sequencing (New Zealand Genomics Limited [NZGL], Massey Genome 
Centre, Palmerston North, New Zealand). 
16S library preparation and Illumina MiSeq DNA sequencing 
 
The V3-V4 regions of the 16S rRNA were used by NZGL to prepare barcoded 
amplicon libraries for each sample. The 16S rDNA in each patient sample was PCR 
amplified with primers that included a unique ‘barcode’ sequence to identify the 
nature of the sample. This allowed all PCR products from all samples to be pooled 
and sequenced at once as the barcode sequence (within individual sequence reads) 
would identify that DNA’s source. The libraries were then pooled by equal molarity 
before being loaded onto the Illumina MiSeq runs. Quality control checks were 
carried out at each step. 
Sequencing data analysis 
 
The software Quantitative Insights Into Microbial Ecology (QIIME) version 1.5.0 was 
used to analyze the sequences (Caporaso et al., 2010). QIIME was used to generate  a 
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taxonomic overview of the samples and then taxonomic profiles of the individual 
samples were compared using functions in QIIME to look for similarities and 
differences between samples via a variety of output methodologies. The overall aim in 
this thesis was to compare bacterial populations of the control and intervention groups 
at two different time points, prior to treatment and after the 1-month intervention. 
Later, molecular findings will be compared with the clinical findings, and detected 
operational taxonomic units (OTU) will be further analysed further. Widely used in 
large-scale characterisations of microbial communities, Operational Taxonomic Units 
(OTUs), by definition, are clusters of similar 16S rRNA sequences representing basic 




The baseline characteristics of the participants are summarised in Table 3.1. Age 
and sex distribution were very similar (Table 3.1). 
 










<14 years 14 (22%) 22 (34%) 
≥14 years 18 (28%) 10 (16%) 
 
Sex (N, %) 
Male 12 (19%) 11 (17%) 
Female 20 (31%) 21 (33%) 




Data pre-processing initial read analysis 
 
There were 130 samples sent for processing (64 from participants and one negative 
control at each time point). The numbers of processed sequences per sample are 
shown in Table 3.2 below. The samples are presented in two columns. In the first 
column are ‘A’ samples and the second column are ‘B’ samples. The ‘A’ samples 
represent those taken at baseline (T=0) and the ‘B’ samples represent those taken 1- 
month post-treatment (T=1). Each number following the ‘A’ or ‘B’ represents the 
individual participant the sample is from (1-64 for participants, 65 for controls). It can 
be seen that there were approximately 9.47 million and 9.44 million total reads for the 
baseline (T=0) and 1-month post-treatment (T=1) samples, respectively. 
 
Two samples, A65_S65 and B65_S65, were excluded from further analysis as 
they were no template (i.e. negative) controls. One patient sample (B38_S38) was 
excluded due to a very low number of sequence reads with poor quality, and thus this 
patient’s corresponding T=0 sample A38_S38 was also excluded, to ensure 
consistency in the comparisons of our data. This patient was a 14-year-old female in 
the probiotic-consuming group. The remaining 126 samples (two from each of 63 
patients) were then analysed with QIIME and Phyloseq software packages. 
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The number of sequence reads per sample – excluding the negative control 
samples A65_S65 and B65_S65 – ranged from 16,972 to 342,881 with an average of 
147,651, a standard deviation of 50,060, and a coefficient of variation of 0.339. The 
average fraction that individual patient samples contributed to the total sequences was 
approximately 1.56% with a standard deviation 0.53%. 
Table 3.2. Sequences per sample at two time points. 
Baseline After 1-month intervention 
(Green: high number of sequences; red: low number of sequences). 
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Thus, the initial range of sequence reads for the full samples was very large. We 
therefore trimmed the data at 3,500 reads per sample and used these subsampled reads 
for subsequent analyses. An initial comparison of these subsamples with their original 
samples revealed that the proportions of species were comparable and thus the 
subsampled data were representative and used for subsequent analyses. 
Taxonomic representation of oral microbiota 
 
QIIME provided a detailed analysis of the oral samples and a large amount of data. 
Due to the complexity of the analyses, this thesis will provide a general observational 
overview of the findings from the sequencing procedures to provide early insight into 
whether the probiotics effected any change in the participants’ microbiomes. It is 
anticipated that the data will be further analysed in due course. As mentioned 
previously, the authors intend to subject the data to statistical analysis and compare 
the molecular findings with the clinical findings, as well as statistically analyse the 
operational taxonomic units (OTU) detected. 
 
In this thesis, data representing the taxonomy of the oral microbiota of the  126 
samples can be viewed at a variety of taxonomic levels ranging from kingdom down 
to species. In order to reduce the data complexity and for convenience, the results 
will be presented progressively from phylum to species level (Figures 3.2 to 3.5) at a 
relative abundance cut-off value of 0.5%. This means that for any OTU, (i.e. species) 
to be included in the analysis, 5 in 1,000 of the total number of sequence reads for 
that particular oral sample is required. In other words, an OTU that is present at less 
than 0.5% of the total number of OTUs will not be included in the analysis. 
 
Figure 3.2 shows the distribution of phyla across the 126 oral samples with 
the different colours representing different phyla. Despite the obvious complexity 
of Figure 3.2, five phyla are common to all samples (from most to least 
abundant): Firmicutes (i.e. Gram-positive bacteria) > Bacteroidetes > 
Fusobacteria > Proteobacteria > TM7. These five phyla, are known to be 
abundant in the oral cavity as evidenced by earlier diversity studies using next-
generation DNA sequencing (Keijser et al., 2008; Zaura et al., 2009). These 
results confirmed that samples obtained from orthodontic patients were 








istribution of phyla (Y
-axis) from
 all 126 oral sam
ples (X
-axis)  sequenced in this study. 
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Figures 3.3 to 3.5 show the distribution of phyla, genera and species, 
respectively, between the probiotic and control groups at baseline and 1-month time 
points. The upper left bar chart represents probiotic group samples at baseline and the 
upper right bar chart represents the placebo-control group samples at baseline. The 
lower left bar chart represents probiotic group samples taken after the 1-month 
intervention and the lower right bar chart represents the placebo (control) group 
samples taken after the 1- month intervention. Horizontal comparisons reveal 
differences between the two treatment groups, and vertical comparisons show the 
differences between baseline and 1-month post-treatment. Note that in Figures 3.3 
and 3.4, the left-most bar of each of these bar charts represents accumulated 
unassigned genera or species, respectively. 
1. Phylum level 
 
The distribution of phyla is shown in Figure 3.3 for each study group (probiotic and 
control) at baseline and 1-month after intervention. There are few differences between 
the groups at baseline, suggesting randomisation was adequate. Five main phyla 
(Firmicutes, Fusobacteria, Proteobacteria, Bacteriodetes and Actinobacteria) were 
present in both groups in large abundances, while five other phyla (Spirochetes, TM7, 
Synergistetes, GN02 and SR1) were only found in relatively low abundance (Figure 
3.3). Firmicutes were the most dominant phylum found among the two study groups 
at  both time points. In the probiotic group, there was a decrease in the level of 
Firmicutes, relative to baseline, with a concomitant increase in the Proteobacteria 
between the two time points (Figure 3.3). On the other hand, the relative abundance 










































































2. Genus level 
 
Results at the genus level are shown for each study group (probiotic and control) at 
baseline and 1-month after the intervention in Figure 3.4. They are representative of 
species known to inhabit supragingival sites in the mouth. At baseline, both probiotic 
and control groups were comparable, although the probiotic group had slightly less 
Veillonella, Selemonas, Rothia and Neisseria than the probiotic group and slightly 
more Fusobacteria, Prevotella and Corynebacteria (Figure 3.4). 
 
After the 1-month intervention, the probiotic group shows a decrease in several 
genera, namely Veillonella, Selenomonas, Prevotella, Leptotrichia, Corynebacterium, 
Capnocytophaga and an increase in Aggregatibacter, Cardiobacterium, 
Fusobacterium, Haemophilus, Rothia and TG-5. 
 
After 1-month, the control group also shows a decrease in Veillonella, 
Selenomonas, and Streptococcus like the probiotic group, but also shows a decrease in 
Actinomyces, Neisseria and Rothia. This group shows an increase in Haemophilus, 
Fusobacterium, and Cardiobacterium, like the probiotic group, but also an increase in 
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3. Species level 
 
The distribution of species with a relative abundance of >0.5% (i.e. >5 in every 1,000 
sequences) for each study group at baseline and at 1 month post-intervention is shown 
in Figure 3.5. The administration of the probiotic strain appeared to have had little 
effect on the microbiota (Figure 3.5). Interestingly, most of the sequence reads were 
included in the “unassigned” group (see leftmost bar of each chart). At baseline, both 
groups had comparable levels of each species although the probiotic group had 
slightly elevated levels of Streptococcus sobrinus, Selenomonas noxia and Prevotella 
melaninogenica when compared to the control group. It had decreased levels of 
Rothia dentocariosa. Any differences were not deemed to be statistically significant. 
 
After 1 month, the probiotic group had a slight increase in Rothia dentocariosa and 
Haemophilus parainfluenzae and a reduction in Veilonella dispar, Selenomonas noxia 
and Prevotella melaninogenica. The control group also had an increase in 
Haemophilus parainfluenzae but a decrease in Rothia dentocariosa and a decrease in 
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A number of reviews have been published over the past decade to demonstrate the 
effects of probiotics on general oral health of dental patients (Meurman, 2005; 
Twetman and Stecksen-Blicks, 2008; Stamatova and Meurman, 2009; Teughels et al., 
2011; Cagetti et al., 2013; Laleman et al., 2014; Gruner et al., 2016). However there 
is a great variation within these studies that make comparisons difficult and 
unreliable. Some of these variations include differences in the probiotic strains, the 
concentrations of bacteria per dose, the, dosage regimen, intervention times, sampling 
sites, delivery methods, and ages and composition of the study populations. 
Moreover, there have been different molecular methods for the analysis of bacterial 
microbiota. Extrapolating findings from a general dental population to an orthodontic 
population is unwise considering the different oral environment in orthodontic 
patients with intra-oral appliances. Hence, there is a need to investigate the use of 
probiotics in an orthodontic patient cohort as these patients experience a much higher 
level of plaque accumulation resulting from orthodontic appliances. Due to the 
variances in these studies, this discussion will focus mostly on comparisons of results 
obtained in this study with the 5 studies published on orthodontic patients to date 
(Cildir et al., 2009; Jose et al., 2013; Pinto et al., 2013; Ritthagol et al., 2013; Gizani 
et al., 2015). 
 
The aim of this study was to assess the effects of an orally-administered 
probiotic, Streptococcus salivarius M18, on the microbiome of orthodontic patients. 
To the best of our knowledge, it is the first clinical trial to utilize a probiotic of oral 
(rather than intestinal) origin in orthodontic patients, and to assess the microbes using 
next-generation DNA sequencing technology. 
Participation rates and compliance 
 
A strength of this study was the zero withdrawal rate and the good overall compliance 
of participants. The zero withdrawal rate could have been attributed to the utilisation 
of e-mail and text message reminders (provided 24 hours prior to scheduled 
appointments), as well as the mailing of an appointment card. Good compliance could 
be due to daily morning and night text message reminders during the period of the 




The random assignment of participants into the two groups protected against selection 
bias as the randomisation was computer-generated. Participants in both treatment 
groups were blinded as to whether their lozenge was the placebo or probiotic due to 
identical manufacturing protocols for both sets of lozenges. The clinician was blinded 
to the group of each patient, thereby preventing differential treatment of the two 
groups. The statistician and personnel carrying out the laboratory-based work and 
bioinformatics were all blinded to ensure objective analysis of the results. Only once 
the raw data had been processed and the results of analyses produced were all 
research team members informed (by BLIS Technologies) as to which group was 
receiving the probiotic lozenge. Collectively, these factors minimised any bias and 
allowed a much greater confidence to be placed in the results of this trial. 
Molecular methods 
 
Oral biofilms, like any biofilms in nature, are very complex microbial communities. 
Traditional culture-based microbiological techniques have uncovered many species, 
some of which are found in high abundance in the oral cavity. The major benefits of 
next-generation sequencing (NGS) techniques over traditional microbiology is the 
ability to detect non-culturable microorganisms and that these low-abundance 
microorganisms can be detected by their molecular signatures (Muyzer and Smalla, 
1998). Given the complexity of the oral microbiota implicated in biofilm-related 
diseases such as halitosis, gingivitis and white spot lesions (Socransky and Haffajee, 
2002; Kazor et al., 2003; Socransky and Haffajee 2005; Taipale et al., 2012; Tanner 
et al., 2012), next-generation molecular methods are useful in providing enough 
sensitivity to detect some of the critical bacterial changes in patients and can provide 
a more in-depth microbial profile analysis of biofilm samples. 
 
This study is the first to use NGS with an orthodontic population. The data 
analysed and the associations made, will be a valuable addition to the microbiological, 
dental and orthodontic literature. Due to the complexity of the data generated by 
QIIME and Phyloseq, and also due to time constraints, this thesis will focus only on a 
small proportion of the overall findings collected in this study. 
 
The Phyloseq package employed was useful in its ability to generate a variety of 
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graphical outputs for the dataset. It does, however, have some issues in the way in 
which the data are presented, such as the single taxonomy plots reordering the 
taxonomic assignments from the most abundant to the least, which is something 
QIIME does not do. This can make identification a little complex. However, the 
ability to generate plots such as such as the bar charts representing the taxonomy in 
this study is a strength. 
Effects of probiotic consumption on the oral microbiome 
 
The results from the trial presented in this thesis showed that consumption of 
probiotic lozenges for 1 month has little effect on the patient’s microbiome. 
 
From a microbiological perspective there is interest in the changes in pathogens 
already known to dentists as well as in new, unculturable species. The main pathogens 
associated with gum diseases such as gingivitis and periodontitis are P. gingivalis, 
Treponema denticola, Tannerella forsythia and Aggregatibacter 
actinomycetemcomitans (Ishikawa et al., 2003). Many bacterial species have been 
suggested as the main causes of halitosis, with volatile sulphur compounds (VSCs) 
produced by these bacteria contributing to the malodour (Kang et al., 2006). 
Fusobacterium nucleatum and other proteolytic anaerobes are the main suspects 
(Burton et al., 2005). The most common cariogenic bacteria are the mutans 
streptococci (mainly Streptococcus mutans), which initiate the caries process and 
lower the pH to below the critical pH of 5.5 (at which enamel begins to demineralise), 
and the lactobacilli, which then establish as the oral pH drops to ~4.5-5.0. 
 
Most microbiological studies have used culturing techniques rather than 
molecular techniques, and so the identity of all the bacteria in plaque (or saliva) is 
largely unknown. Past studies on probiotic effects have mainly assessed levels of S. 
mutans and lactobacilli, thereby providing a better understanding of the probiotic role 
in caries rather than gingival health and halitosis. 
 
In three of the five probiotic studies performed on an orthodontic population, the 
strains Lactobacillus paracasei SD1 (Ritthagol et al., 2013), Bifidobacterium animalis 
subsp. lactis DN-173010 (Cildir et al., 2009) and a probiotic of unknown strain and 
concentration (Jose et al., 2013) significantly decreased the levels of mutans 
streptococci when delivered in milk, yoghurt, curd and toothpaste respectively. 
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Analysis of similar studies using Bifidobacterium probiotic strains in patients 
without orthodontic braces, indicates that it is likely there would be a similar 
reduction in salivary mutans streptococci in orthodontic patients consuming yoghurt 
containing the probiotic Bifidobacterium animalis subsp. lactis DN-173010 daily 
(Cildir et al., 2009) rather than no change as found by Pinto and colleaugues who used 
the same strain (Pinto et al., 2013). 
 
The contrasting results of these two studies above, despite their similar designs 
and sample sizes, could be attributed to the yoghurt used to deliver the probiotic. The 
yoghurt may influence the cariogenic potential of the microbiota and colonisation of 
the oral cavity by the probiotic strain (Pinto et al., 2013). Studies using dairy products 
to deliver their probiotic are more commonly associated with a reduction in mutans 
streptococci. However, it should be noted that studies using Bifidobacterium have 
shown less consistent outcomes over time compared to those employing Lactobacillus 
reuteri and Lactobacillus rhamnosus strains in recent reviews on dental patients 
without fixed appliances. 
 
On the other hand, Ginzani and colleagues, using a strain of L. reuteri, found no 
difference in the levels of mutans streptococci and lactobacilli in saliva, or any 
difference in the incidence of white spot lesions in orthodontic patients (Gizani et al., 
2015). This study used lozenges as the mode of delivery, had a good sample size and 
intervention period of 17 months. It was also the first study to report white spot lesion 
incidence as an outcome, rather than the traditional reporting of surrogate measures of 
caries such as mutans streptococci and lactobacillus levels. The shortcomings of using 
such surrogate measures is discussed below. 
 
As previously mentioned, the detection of specific bacteria is limited by the 
molecular techniques used. The majority of studies have opted for chairside kits or 
microbial culture, possibly due to financial constraints and possibly the unavailability 
of next-generation sequencing services. Jose and colleagues (Jose et al., 2013), 
represents one of the few groups to have used the sensitive and reproducible 
quantitative real-time polymerase chain reaction (qPCR) technique to examine the 
levels of S. mutans in a cohort of 60 orthodontic patients who consumed a probiotic 
for 30 days. In that study, a significant decrease in S. mutans levels was observed. 
However, a dairy product was used as the mode of delivery and the probiotic strain 
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was not disclosed. 
 
The lack of significant changes in the microbiota of our participants in both 
groups is contrary to the results of other researches who showed a significant decrease 
in mutans streptococci when probiotics were tested in non-orthodontic patients. The 
consumption of L. rhamnosus GG seems to decrease mutans streptococci counts when 
consumed for 3 weeks in the form of cheese or for 7 months when delivered in milk 
(Nase et al., 2001; Ahola et al., 2002). Similarly, L. reuteri-containing products have 
shown this reduction in mutans streptococci levels (Nikawa et al., 2004; Caglar et al., 
2005; Çaglar et al., 2006; Caglar et al., 2007; Caglar et al., 2008). 
 
These differences may be explained by the differences in study designs. Using 
the study by Calgar and colleagues (Caglar et al., 2007) as an example, saliva samples 
were assessed rather than plaque samples, participants were asked to chew gum three 
times daily after meals for three weeks and used a different probiotic strain. It is 
known that saliva is abundant in S. mutans, whereas plaque from teeth is less likely to 
have high concentrations of S. mutans unless the participant is experiencing early 
caries and the pH is decreasing thereby providing an environment in which S. mutans 
flourishes (Marsh, 2009). These factors alone could have contributed to the difference 
in results independent of the difference in the oral conditions of a non-orthodontic 
dental population compared to an orthodontic one. 
 
DNA fragments representing S. salivarius were present in samples from both 
groups, albeit in small numbers, this was to be expected as S. salivarius is more 
commonly found in saliva samples and on the tongue. Its detection in plaque samples 
is possibly due to saliva coating the oral surface. It would be interesting to assess the 
abundance of F. nucleatum, W. cibaria and proteolytic anaerobes as these microbes 
play a role in halitosis, which is a common issue in orthodontic patients, although 
samples from the tongue would be more appropriate for this. 
 
Masdea and colleagues found that S. salivarius K12 has antimicrobial activity 
against bacteria involved in halitosis. They found that S. salivarius K12 suppressed 
the growth of all Gram-positive bacteria they tested, but the bacteria were inhibited to 
varying degrees (Masdea et al., 2012 . Eubacterium sulci ATCC35585 was the most 
sensitive strain, while Solobacterium moorei was inhibited less (Masdea et al., 2012). 
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Surrogate measures of caries 
 
Although the majority of probiotic studies have examined the effect of certain 
probiotic strains on surrogate measures of caries incidence, such as S. mutans levels, 
for obvious ethical and budget reasons, only a handful of studies have examined,  
more usefully, caries as an outcome measure. In our study we took clinical photos at 
each time point of each participant so that assessment of white spot lesions (early 
caries) as an end point can be investigated in this population after their orthodontic 
treatment. 
 
One may question the value of studies that publish microbiological data over 
caries incidence as there is concern regarding the validity of using S. mutans levels 
alone as an indicator of caries. This is mainly due to the discovery that caries can 




Microbial sampling method 
 
Rather than sampling plaque, we could have sampled saliva. An earlier study has 
shown that the composition of salivary microbiota is representative of that found on 
dorsal and lateral surfaces of the tongue (Mager et al., 2003), which suggests that this 
method would have been appropriate to detect halitosis-causing microorganisms. 
Saliva samples for microbiological studies on gingival health and caries have also 
been used with success. However, a limitation may be that the saliva composition 
represents the entire oral microbiota, so changes on tooth surfaces and gingiva could 
be missed. Therefore we deemed our method of pooling the plaque of all surfaces of 
all teeth with braces as the most suitable to provide an accurate representation of the 
biofilm profile of each patient at the site most likely to experience the most 




It is thought that the participant’s response to probiotic treatment could be influenced 
by their disease stage and the microbes occupying the diseased site (Devine and 
Marsh, 2009). 
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In this study, the numbers of bacteria in each sample were shown as a proportion 
of each sample’s total bacterial count. It would be beneficial to have quantifiable 
bacterial numbers to make a statistical rather than an observational comparison 
between subjects at different time points and between the two groups. Additionally, 
understanding the proportion and type of bacteria present is useful, but we are 
unaware of the relevance of this by not knowing how these bacteria interact within 
their host environment. 
Influence of gender on results 
 
In the present study, the female:male participant ratio was 2:1. There was no 
difference between genders in their compliance with consuming the lozenges. 
Furthermore, the probiotic did not perform better in either gender, although the female 
participants generally had better oral hygiene status than the male participants which 




A pre-treatment regime using the broad-spectrum antimicrobial chlorhexidine before 
the consumption of the probiotic lozenge was used in this study. The rationale for this 
regime was to rid the mouth of its bacterial load thereby allowing the ‘good’ probiotic 
bacteria to colonise the oral microbial surfaces during administration (Aminabadi et 
al., 2011). The pre-treatment was deemed to have little lasting effects as a previous 
study on the effect of chlorhexidine on the oral microbiota showed that microbial 
populations could recover to pretreatment levels within 24 hours (Rindom Schiøtt et 
al., 1970). The mouth rinse was used by both groups so any changes caused by the 
chlorhexidine should have been similar. 
Duration of the study 
 
There has been a huge variation in the duration of treatments reported in previous 
studies using probiotic strains. Since plaque builds up around orthodontic braces 
within 24 hours, we were confident that a 4-week intervention with a 3-month follow- 
up was sufficient to provide a glimpse as to whether probiotics could provide a 
beneficial effect on plaque biofilm. However, based on the results obtained in this 
study, if the intervention period had been extended more meaningful conclusions may 
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have been obtained. This notion is supported by some authors who have seen a 
significant reduction in plaque of children only after three months and suggest that an 
intervention period longer than 1 month is necessary for an effect to be obvious 
(Burton et al., 2013a). However, studies such as this were in patients without braces, 
where the oral environment is quite different and plaque build-up is a lot slower. 
 
Studies of probiotic use in non-orthodontic dental populations are usually focused 
on whether consumption of the probiotic has any beneficial effect on the oral health of 
the host. There is also interest in whether these beneficial effects persist after 
cessation of consumption, i.e. whether the probiotic strain colonises the oral cavity for 
long periods (Burton et al., 2013a). 
 
Since orthodontic treatment is usually of 1-1.5 years in duration, and the larger 
levels of biofilm assault only last this long, we were more interested in the benefit 
provided to the patient with the regular consumption of the probiotic for the duration 
of orthodontic treatment. This is fitting, as the current evidence suggests that when the 
consumption of probiotics ceases, the probiotic bacteria are slowly eliminated from 
the mouth (Burton et al., 2013a) through natural shedding via salivary flow. Although 
it would be beneficial to see a persisting positive action of probiotics in biofilms after 




We did our utmost to limit confounders in this study. While we believe counfounders 
were minimised, it was impossible to monitor each participant’s every move. There 
are a number of factors that may have influenced plaque build-up and the presence of 
pathogenic bacteria. Some of these include: the diet of participants; home access to 
additional antibacterial products; stimulation of saliva by chewing sugar-free gum; 
changes in brushing and flossing technique; and swallowing or chewing the lozenge 
rather than sucking it, thereby washing away the probiotic from the mouth. The type 
of orthodontic auxiliaries used by the respective postgraduate orthodontic students 




Further analysis of the data by a biostatistician could well provide interesting insight 
into the composition of the orthodontic biofilm. Our molecular methods enabled a 
highly sensitive technique to identify species that are difficult to discover with 
traditional methods. Although a full analyses of the data could not be completed, there 
should be a number of interesting observations when the data is analysed further. It 
should be stated that due to resource constraints, only the oral samples from baseline 
and 1-month time points were processed and subjected to next-generation DNA 
sequencing. Since we obtained plaque samples from the participants 3 months after 
the 1-month intervention, it would be interesting in the future to assess these 
adequately stored samples, to see whether the probiotic strain used in our study 






Sucking probiotic-containing lozenges twice daily for one month did not change the 
microorganism compositions in the plaque samples from our orthodontic cohort 
significantly. Therefore, it is not clear if sucking probiotic lozenges over a short term 
would reduce caries or gingivitis risk in orthodontic patients. 
 
Probiotic lozenge consumption, even as a supplemental practise, should not be a 
substitute for a comprehensive preventive dental programme that includes the 
application of fluoride, hygiene practices and regular dental visits. The evidence 
regarding the benefits of the use of probiotics in the prevention of dental disease is 
limited and studies of longer duration, ideally with clinical output measures, are 
needed before their routine use can be justified for oral disease prevention. 
 
Oral diseases are difficult to treat due to their polymicrobial causes, non-specific 
aetiology, high cost of adjunctive microbiological testing, and the required skills for 
data interpretation. Before probiotic treatment is dismissed, future molecular methods 
that do not just determine the microbial taxa present in oral biofilms, but also help us 
to understand the functions and activities of each microbial sub-community within the 
biofilm, would be most beneficial. 
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In conclusion, although probiotics have been known for their benefits in general 
(intestinal) health, their application in oral health, especially with orthodontic patients, 
is still very much under development and well-conducted comparable studies are 
scarce. Therefore, well-designed randomised controlled (preferably longitudinal)  
trials and the utilisation of advanced molecular techniques are needed to provide 
further scientific clinical evidence on this promising, yet poorly understood topic 
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Biofilm formation around fixed orthodontic appliances causes a number of clinical 
consequences, such as enamel demineralisation (white spot lesions), gingival 
inflammation and halitosis (Kang et al., 2006;; Srivastava et al., 2013; Zurfluh et al., 
2013; Ren et al., 2014). Patients undergoing orthodontic treatment have a higher risk 
of biofilm-related complications due to impeded oral hygiene, compromised natural 
oral cleansing and extra retentive surfaces provided by fixed appliances (Lee et al., 
2001; Ogaard, 2008). Traditional methods of biofilm removal include mechanical 
cleaning (e.g. tooth brushing and flossing) and chemical therapy (e.g. fluoride 
toothpaste, antibacterial mouthwashes). However these methods are not entirely 
reliable at reducing biofilm formation and so the prevalence of biofilm-induced 
clinical issues such as white spot lesions remain high (Srivastava et al., 2013; Ren et 
al., 2014). 
 
Oral probiotics, on the other hand, can exert their effects on the biofilm by 
shifting the micro-ecological balance to favour beneficial non-pathogenic bacteria 
(Reid et al., 2011). It is apparent that the role of probiotics in oral health is gaining 
acceptance (Meurman, 2005; Twetman and Stecksen-Blicks, 2008; Stamatova and 
Meurman, 2009; Teughels et al., 2011; Laleman et al., 2014; Gruner et al., 2016). 
Oral probiotics may be beneficial for managing biofilm formation in patients with 
fixed appliances. In this triple-blind randomised controlled trial, we investigated the 
efficacy of oral probiotic Streptococcus salivarius M18 on plaque index (PI), gingival 
index (GI) and halitosis measurements in patients with fixed appliances. 
 
 
The effect of oral probiotics on PI and GI 
 
After a 1-month intervention, the PI and GI did not change significantly in the oral 
probiotic group or placebo-control group, at all time points (baseline, 1-month and 3- 
month) (Chapter 2). This may be due to the relatively short intervention period (only 
1-month active treatment and 3-month treatment-free follow-up) or the inability for S. 
salivarius M18 to exert its effects on the biofilm (Chapter 3). Similarly the taxonomic 
profiles showed little changes between probiotic and placebo-control group after the 
1-month intervention. The similar taxonomic profiles between groups at baseline, 
suggest that the sampling and randomisation was carried out well (Chapter 3). 
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The effect of oral probiotics on halitosis 
 
The volatile sulphur compounds (VSCs) produced by oral biofilms, especially 
anaerobes located on the dorsum of the tongue, are considered one of the most 
common contributors to halitosis (Loesche and Kazor, 2002). The VSC levels in 
orthodontic patients have been found to be relatively higher than populations without 
fixed appliances (Babacan et al., 2011; Sokucu et al., 2016). 
 
In the study, the VSC levels of the probiotic group significantly decreased after 1 
month of consuming two oral probiotic lozenges daily, and decreased the levels even 
further after a 3-month treatment-free follow-up (Chapter 2). This may be due to the 
probiotic being able to effectively neutralise the pathogens responsible for halitosis 
(e.g many Gram negative bacteria), or perhaps that S. salivarius M18 is able to remain 
longer at the site where these halitosis-causing pathogens are found-the tongue 
(Chapter 3). Since we did not sequence our 3-month post intervention samples, we 
were unable to analyse the changes in the microbiota over this time period to see if 
there were any distinct changes that correlated with these clinical findings. However 
the similar reduction in VSC levels of both probiotic and placebo-control groups after 
1-month was supported by a similar distribution of species in both groups with a 
relative abundance of >0.5% at this time point. 
 
Probiotics have been used as a treatment modality in dentistry, with early studies 
using a probiotic such as S. Salivarius K-12 showing promise and warranting further 
investigation. Analysing the microbial profiles of the biofilm with molecular 
techniques such as by direct PCR-based amplification of the 16S ribosomal RNA 
gene, followed by sequencing of the PCR products using next-generation DNA 
sequencing (Ion Torrent) technology is not done routinely. This technique provides a 
‘gold standard’ for bacterial identification and ultimately allows one to identify the 
known species in an oral biofilm and possibly identify microorganisms that cannot be 
cultured. These methods improve our understanding of microbiota-host interactions, 
and will impact the future development of diagnostic tests. So far, all efforts have 
been focused on identifying members of the oral microbiome with a taxonomic survey 
87	 
Clinical implications and future research 
 
Oral probiotic S. salivarius M18 was found to improve halitosis in patients with fixed 
orthodontic appliances in this study, but it did not reduce plaque or gingival indices. 
The probiotic had little effect on taxonomic profiles and ultimately the long-term 
effectiveness of S. salivarius M18 is still unclear. 
 
Future studies should be of longer duration, with interventions longer than 3- 
months. Previous studies evaluating caries surrogates are not helpful as some patients 
that have an abundance of these bacteria, have little experience of adverse effects. 
Similarly, although molecular methods such as next generation sequencing enable us 
to provide evidence of bacteria unexposed by culture methods, they merely show us 
taxonomic profiles and abundances of certain bacteria. This is useful for identifying 
new species, but since it is becoming clearer that probiotics have different effects on 
different individuals, it is perhaps the interactions within the individual biofilms that 
are of more importance when concluding on their effects. Once we are able to discern 
these, we should have a better understanding of their potential. Additionally, 
conducting long-term studies that assess clinical outcomes would be of huge benefit, 
although ethical considerations around this may be a hindrance. 
 
Although probiotics administered by different modes of delivery have largely 
shown beneficial results, comparisons of delivery methods, concentrations and 
assessing how long they remain in the oral cavity, would be worthwhile. So far, 
observation of the current literature suggests dairy based delivery methods show the 
most promise at having an effect in the oral cavity. 
 
Streptococcus salivarius K12 and M18 are the only probiotics to have been 
developed from the mouth, for the mouth. Albeit a small number, the majority of 
studies investigating these probiotic strains have shown positive results, however the 
strain was developed and patented in New Zealand, which has possibly made its 
obtainability for research more difficult. The commonly available L. reuteri, L. 
rhamnosus and Bifidobacterium species in European countries are used in the 
majority of research on this topic. Therefore it would be worthwhile conducting a 
well-designed, high-powered study to compare strains of probiotics and their effects 
on disease incidence. 
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The combination of a probiotic such as S. salivarius M18 with a Lactobacillus 
probiotic may have synergistic effects. Utilising an antibacterial sugar substitute such 
as Xylitol or supplementation with fluoride or Casein phosphopeptide-amorphous 
calcium phosphate (CPP-ACP), could hold potential too. It seems that a single 
probiotic strain may be lacking the broad-spectrum effect needed to positively 
influence the majority of the bacterial population in an individual host’s microbiome. 
 
Most importantly however, future trials should begin to follow a systematic 
method of conducting and reporting their studies so that research around the globe can 
be compared adequately and ‘apples’ can be compared with ‘apples’ so quicker 
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Oral biofilms cause several clinical problems in general dental patients and 
orthodontic patients. Fixed appliances make it difficult to maintain good oral hygiene, 
compromise natural oral cleansing and provide additional biofilm retention areas.  
This contributes to an increased risk of biofilm-related problems such as enamel 
demineralisation, gingivitis and halitosis. Traditional mechanical and chemical 
biofilm management approaches all have limitations. 
 
Probiotics pose a promising method for managing biofilm formation. Chapter 1 
reviews the historical perspectives and proposed mechanisms of action of probiotics 
and discusses the various strains used in general oral health and orthodontics. It also 
scrutinises past trials that report their effects. From this review, we outline the 
limitations of past studies and provide guidance on possible future directions and 
considerations for further studies on oral probiotics. In this trial we intended to 
address many of the shortcomings that are apparent in past studies to get a more 
accurate idea of the effects of probiotics in patients undergoing orthodontic treatment. 
 
Using a triple-blind randomised placebo-controlled clinical trial, we assessed the 
effects of oral probiotics on clinical parameters such as plaque index (PI), gingival 
index (GI) and volatile sulphur compounds (VSCs) in Chapter 2. We found no 
significant difference in GI and PI between the two groups after the 1-month 
intervention or at the 3-month treatment free follow-up. There was a statistically 
significant reduction in VSC levels in the oral probiotic group at all time points. This 
suggests that the oral probiotic may improve bad breath in orthodontic patients. 
 
In order to better understand the effects of probiotic therapy on the oral 
microbiome of orthodontic patients, Chapter 3 investigated the changes of oral 
microflora using Next Generation Gene Sequencing. Taxonomic profiles of probiotic 
and place-controlled groups were similar at baseline and after intervention, suggesting 
S.salivarius M18 had little effect on microbiota. The 1-month intervention period was 
very short. Future longer duration, well-designed studies, assessing clinical outputs 
are needed before orthodontists can justify biofilm management with probiotics in 
patients undergoing fixed appliance treatment.  
 
Clinical relevance: Probiotic use may help with combating halitosis in 
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Appendix 1. Independent peer review and correspondence 
 
23rd June 2014 
 
 
Dear Dr Mei, 
 
Re: Efficacy of the oral probiotic Streptococcus salivarius in managing biofilm formation in patients 
wearing fixed orthodontic appliances: A double-blind randomised placebo-controlled trial. 
 
Thank you for asking me to critically evaluate your research protocol. Your project looks interesting 
and clinically significant to the field of Orthodontics. The study design seems appropriate and the 
method is well constructed. 
 
However I encourage you to consider the following points: 
 
1) Exclusion criteria 
 
a) Will you consider participants who live in both fluoridated and non-fluoridated areas in Dunedin 
as fluoride can act to reduce biofilm levels? 
b) Will you consider participants who are unable to brush their teeth themselves (e.g. special needs, 
physical disabilities, etc.). These participants could be disadvantaged in their ability to remove plaque 
from their teeth (without external assistance). 
 
2) 1-month treatment intervention 
 
Will this be a long enough period to gain meaningful results? The minimal time period required to 
detect a clinically significant effect does not seem clear in your proposal. 
 
3) “If any serious adverse events are observed in any of the participants, the study will be terminated 
immediately”. 
 
Can you please elaborate on the nature and likelihood of these potential risks? 
 






Discipline of Orthodontics 
University of Otago, New Zealand 
E: joseph.antoun@otago.ac.nz 
P: +64 3 479 7071 




10th July 2014 
 
 
Dear Dr Antoun, 
 
Many thanks for your feedback with regards to our research protocol. I will address each issue 
under the heading you provided. 
 
1) Exclusion criteria. 
 
a) Will you consider participants who live in both fluoridated and non-fluoridated areas in Dunedin 
as fluoride can act to reduce biofilm levels? 
 
This is a valid point. We will exclude any participant living in Allanton, Waikouaiti and Mosgiel as 
these areas are non-fluoridated and the participants could provide biased results. 
 
b) Will you consider participants who are unable to brush their teeth themselves (e.g. special needs, 
physical disabilities, etc.). These participants could be disadvantaged in their ability to remove plaque 
from their teeth (without external assistance). 
 
Participants who are unable to physically brush their teeth will be excluded from the study as they 
could affect the reliability of results. 
 
2) 1-month treatment intervention. 
Will this be a long enough period to gain meaningful results? The minimal time period required to 
detect a clinically significant effect does not seem clear in your proposal. 
 
Studies carried out by other authors (Burton et al., 2013), suggest that a 1-month intervention will 
be sufficient to obtain reliable results on the effect of Streptococcus salivarius on biofilms. 
 
3) “If any serious adverse events are observed in any of the participants, the study will be terminated 
immediately”. Can you please elaborate on the nature and likelihood of these potential risks? 
 
The lozenges we intend to use, will contain probiotic strain Streptococcus salivarius M18. All humans 
have Streptococcus salivarius in their oral cavity. Streptococcus salivarius are common in the mouth and 
make up to 40% of all the bacteria in the normal healthy mouth. 
However the probiotic product provided by BLIS technologies Ltd, is made on equipment that 
also processes milk, soy and wheat. Any adverse events are likely to be associated with milk, soy, 
wheat protein allergies. The prevalence of these allergies is in the range of 1-2% (Kattan et al., 2011), 
which suggests the chances of them occuring is extremely low. 
 
Once again, many thanks for your feedback. 
Kind Regards 
Dr Peter Li Mei 
 
 
1. Burton JP, Drummond BK, Chilcott CN, Tagg JR, Thomson WM, et al. (2013) Influence of the probiotic Streptococcus 
salivarius strain M18 on indices of dental health in children: a randomised double-blind, placebo-controlled trial. J Med 
Microbiol 62: 875-84. 



































As a current patient under fixed orthodontic treatment by Azza, Catherine, Yana or Gareth, 
you/your child is being considered for inclusion in a randomised controlled trial. 
 
The study is being conducted at the Orthodontic Department, Dental School. 
 
It is in a new and exciting area of research and we are excited to be carrying it out from July 
this year. We have enclosed details on the study. 
 
We ask that you please read the attached forms: 
 
Green-information sheet for child participants 
Grey-information sheet for parents 
Blue-consent form for parents/caregivers (to be signed please) 
Yellow-consent form for child participants (to be signed and ethnicity stated please) 
 
We ask that you please fill in the completed forms in the self addressed envelope as soon as 
you are able. 
 
Should you have any questions, please feel free to ask your treating Orthodontic Student 
(Azza, Catherine, Yana or Gareth) for more information at your next appointment or 
alternatively I can be reached at: benga221@otago.ac.nz. 
 
Many thanks in advance. 
Kind Regards, 
 




Appendix 5. Information sheets and informed consent forms 
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Efficacy of the oral probiotic Streptococcus salivarius in managing 
biofilm formation in patients wearing fixed orthodontic appliances: 
A double-blind randomised placebo-controlled trial 
 
 
INFORMATION SHEET FOR 
PARTICIPANTS or PARENTS / GUARDIANS ETC. 
 
 
Thank you for showing an interest in this study. Please read this information sheet carefully 
before deciding whether or not to take part. It would be great if you decided to take part, 
however if you decide not to, your braces treatment will not be affected by your decision. 
 
What is the aim of the project? 
 
Braces make it more difficult to brush teeth properly and can increase the build-up of 
plaque (which houses bad dental bugs) in these hard-to-brush areas. A large amount of 
plaque can lead to problems like white spots on teeth, bleeding gums and bad breath. 
 
Toothbrushes, mouth rinses and toothpastes can help stop plaque build up on teeth, but 
they do not always work. 
 
We are looking at a new way to stop bad bugs growing in mouths and on teeth. We are 
using lozenges that have good friendly bugs which we hope will fight and replace the bad 
bugs in mouths. These good bugs are called probiotics. 
 
These good bugs have shown to help fight bad bugs in all parts of the body, but few dentists 
and scientists have tried using them in the mouth. 
 
If these bugs work like we hope they will, they could stop white spots from developing on 
teeth, improve gum health and freshen breath in patients undergoing treatment with braces. 
 
This study is being done by Gareth Benic, who is a Dentist studying to be an Orthodontist 
at the School of Dentistry, University of Otago. 
 
Who are we looking for? 
Patients wearing braces and being treated at the Dental School. We want patients who are 




We cannot include patients who: 
o wear braces on the inside of their teeth (lingual braces) 
o use a non-fluoride toothpaste 
o use a toothpaste with supplementary antibacterial agents (i.e. Colgate Total) 
o have gum disease 
o have had lots of dental treatment 
o have a health condition (i.e. diabetes) 
o taking antibiotics 
o have dental fluorosis 
o live in non-fluoridated areas (Allanton, Waikouaiti and Mosgiel) 
o use an electric toothbrush 
o are physically unable to brush their teeth themselves 
o smoke cigarettes 
o lactose intolerant 
o allergic to dairy products 
 
Please note that the probiotic product provided by BLIS technologies Ltd, is made on equipment that also processes milk, 
soy and wheat. Any adverse events are likely to be associated with milk, soy, wheat protein allergies. The prevalence of 
these allergies is in the range of 1-2%, which suggests the chances of them occurring is extremely low. 
What will Participants Be Asked to Do? 
First Visit 
Gareth Benic will brush dye onto the participant’s teeth to show the plaque that is on each 
tooth surface. He will then take some quick measurements. The participant will then be 
asked to remove the plaque (that is shown by the dye) by brushing and flossing. Gareth 
Benic will help with this. He will then let the participant rinse with a mouthwash and will ask 
them to suck one of the two lozenges. One will have the good bugs in it and the other will 
have none, but the participants won’t know which lozenge they are getting. 
A months worth of lozenges (plus toothpaste and toothbrushes) will be given to the 
participants to eat at home. We will also give them a sticker chart to help as a reminder to 
take the lozenges. The participant will be asked to suck one lozenge after brushing their 
teeth in the morning and one after brushing their teeth at night. 
 
One month later 
After one month they will come back to the Orthodontic Department to have 
measurements taken again. They can then stop taking the lozenges. 
 
Three months later 
After another three months they will come back to the Orthodontic Department to have 
measurements taken again for one last time. 
 





What will we do? 
• See how much plaque is on each tooth surface as shown by the dye 
• Take a small sample of plaque from the upper front tooth with a little stick. 
• Measure the breath. 
 
Is it safe? 
The good bug (probiotic strain) we are using is S. Salivarius M18 (BLIS Technologies Ltd, 
Dunedin, New Zealand). This product can be bought from shops and has been trialed and 
tested to show that it is safe and will not negatively affect health or well-being. More 
information can be found at: www.blis.co.nz 
 
What information and data will be collected? 
Age, gender, amount and type of bugs in the plaque, and breath measurements. 
 
Privacy protection 
Information will only be used by Gareth Benic and kept completely private. Data will be 
stored in a password-protected database and only Gareth Benic and his supervisors (Dr. Li 
Mei, Dr Nick Heng and Prof. Mauro Farella) will have access to the collected information. 
Furthermore, all the collected information will be destroyed, ten years after the research is 
finished. 
 
Data will be used to: 
Compare plaque, gum and breath measurements with other participants in the study. We 
may use the results of the study for other similar research and publish them in healthcare 
journals or use them in healthcare presentations. 
 
Can participants change their  mind  and  withdraw  from  the  project? 
Participants may withdraw from the study at any time and without any disadvantage of any 
kind. 
 
What if participants have any questions? 
If you have any questions about the project, please feel free to contact us: 
Gareth Benic: 027 305 2448 benga221@student.otago.ac.nz 
Dr. Li (Peter) Mei: 03 479 7480 li.mei@otago.ac.nz 
Prof. Mauro Farella: 03 479 5852 mauro.farella@otago.ac.nz 
 
This study has been approved by the University of Otago Human Ethics Committee. If you have any concerns about the ethical conduct of the     
research you may contact the Committee through the Human Ethics Committee Administrator (ph. 03 479 8256 or email gary.witte@otago.ac.nz). 
Any issues you raise will be treated in confidence and investigated and you will be informed of the  outcome. 
 
Compensation 
In the unlikely event of a physical injury as a result of your participation in this study, you may be covered by ACC under the Accident Compensation    
Act 2001. ACC cover is not automatic, and your case will need to be assessed by ACC according to the provisions of the Accident Compensation Act 
2001. If your claim is accepted by ACC, you still might not get any compensation. This depends on a number of factors, such as whether you are an 
earner or non-earner. ACC usually provides only partial reimbursement of costs and expenses, and there may be no lump sum compensation payable. 
There is no cover for mental injury unless it is a result of physical injury. If you have ACC cover, generally this will affect your right to sue the 
investigators. If you have any questions about ACC, contact your nearest ACC office or the investigator. You are also advised to check whether 






Efficacy of the oral probiotic Streptococcus salivarius in managing 
biofilm formation in patients wearing fixed orthodontic appliances: 
A double-blind randomised placebo-controlled trial 
 
 
INFORMATION SHEET FOR 
CHILD PARTICIPANTS 
 
Thank you for showing an interest in this study. Please read this information sheet carefully 
before deciding whether or not to take part. It would be great if you decided to take part, 
however if you decide not to, your braces treatment will not be affected by your decision. 
 
What is the aim of the project? 
 
Braces make it more difficult to brush teeth properly and can increase the build-up of 
plaque (which houses bad dental bugs) in these hard-to-brush areas. A large amount of 
plaque can lead to problems like white spots on your teeth, bleeding gums and bad breath. 
 
Toothbrushes, mouth rinses and toothpastes can help stop plaque build up on your teeth, 
but they do not always work. 
 
We are looking at a new way to stop bad bugs growing in your mouth and on your teeth. 
We are using lozenges that have good friendly bugs which we hope will fight and replace the 
bad bugs in your mouth. These good bugs are called probiotics. 
 
These good bugs have shown to help fight bad bugs in all parts of the body, but few dentists 
and scientists have tried using them in the mouth. 
 
If these bugs work like we hope they will, they could stop white spots on your teeth, give 
you healthy gums and fresh breath while you are undergoing treatment with braces. 
 
This study is being done by Gareth Benic, who is a Dentist studying to be an Orthodontist 
at the School of Dentistry, University of Otago. 
 
Who are we looking for? 
 
Patients wearing braces and being treated at the Dental School. We want patients who are 




We cannot include patients who: 
o wear braces on the inside of their teeth (lingual braces) 
o use a non-fluoride toothpaste 
o use a toothpaste with supplementary antibacterial agents (i.e. Colgate Total) 
o have gum disease 
o have had lots of dental treatment 
o have a health condition (i.e. diabetes) 
o taking antibiotics 
o have dental fluorosis 
o live in non-fluoridated areas (Allanton, Waikouaiti and Mosgiel) 
o use an electric toothbrush 
o are physically unable to brush their teeth themselves 
o smoke cigarettes 
o lactose intolerant 
o allergic to dairy products 
 
Please note that the probiotic product provided by BLIS technologies Ltd, is made on equipment that also processes milk, 
soy and wheat. Any adverse events are likely to be associated with milk, soy, wheat protein allergies. The prevalence of 
these allergies is in the range of 1-2%, which suggests the chances of them occurring is extremely low. 
 
What will Participants be Asked to Do? 
 
First Visit 
On your first visit, Gareth Benic will brush dye onto your teeth to show the plaque that is 
on the tooth surfaces. He will then take some quick measurements. You will then be asked 
to remove the plaque (that is shown by the dye) in your mouth by brushing and flossing. 
Gareth Benic will help you to do this. He will then let you rinse with a mouthwash and you 
will be asked to suck one of the two lozenges. One will have the good bugs in it and the 
other will have none, but you won’t know which lozenge you are getting. 
A months worth of lozenges (plus toothpaste and toothbrushes) will be given to you to 
eat at home. We will also give you a sticker chart to help you remember to take the 
lozenges. You will be asked to suck one lozenge after brushing your teeth in the morning 
and one after brushing your teeth at night. 
 
One month later 
After one month you will come back to the Orthodontic Department to have 
measurements taken again. You can then stop taking the lozenges. 
 
Three months later 
After another three months you will come back to the Orthodontic Department to have 
measurements taken again for one last time. 
 





What will we do? 
• See how much plaque is on the tooth surfaces as shown by the dye 
• Take a small sample of plaque from your upper front tooth with a little stick. 
• Measure your breath. 
 
Is it safe? 
The good bug (probiotic strain) we are using is S. Salivarius M18 (BLIS Technologies Ltd, 
Dunedin, New Zealand). This product can be bought from shops and has been trialed and 
tested to show that it is safe and will not negatively affect health or well-being. More 
information can be found at: www.blis.co.nz 
 
What information and data will be collected? 




Your information will only be used by Gareth Benic and kept completely private. Data will 
be stored in a password-protected database and only Gareth Benic and his supervisors (Dr. 
Li Mei, Dr Nick Heng and Prof. Mauro Farella) will have access to the collected information. 
Furthermore, all the collected information will be destroyed, ten years after the research is 
finished. 
 
Data will be used to: 
Compare plaque, gum and breath measurements with other participants in the study. We 
may use the results of the study for other similar research and publish them in healthcare 
journals or use them in healthcare presentations. 
 
Can participants change their  mind  and  withdraw  from  the  project? 
Participants may withdraw from the study at any time and without any disadvantage of any 
kind. 
 
What if participants have any questions? 
If you have any questions about the project, please feel free to contact us: 
Gareth Benic: 027 305 2448 benga221@student.otago.ac.nz 
Dr. Li (Peter) Mei: 03 479 7480 li.mei@otago.ac.nz 
Prof. Mauro Farella: 03 479 5852 mauro.farella@otago.ac.nz 
 
 
This study has been approved by the University of Otago Human Ethics Committee. If you have any concerns about the ethical conduct of the     
research you may contact the Committee through the Human Ethics Committee Administrator (ph. 03 479 8256 or email gary.witte@otago.ac.nz). 
Any issues you raise will be treated in confidence and investigated and you will be informed of the  outcome. 
 
Compensation 
In the unlikely event of a physical injury as a result of your participation in this study, you may be covered by ACC under the Accident Compensation    
Act 2001. ACC cover is not automatic, and your case will need to be assessed by ACC according to the provisions of the Accident Compensation Act 
2001. If your claim is accepted by ACC, you still might not get any compensation. This depends on a number of factors, such as whether you are an 
earner or non-earner. ACC usually provides only partial reimbursement of costs and expenses, and there may be no lump sum compensation payable. 
There is no cover for mental injury unless it is a result of physical injury. If you have ACC cover, generally this will affect your right to sue the 
investigators. If you have any questions about ACC, contact your nearest ACC office or the investigator. You are also advised to check whether 







Efficacy of the oral probiotic Streptococcus salivarius in managing 
biofilm formation in patients wearing fixed orthodontic appliances: 
A double-blind randomised placebo-controlled trial 
 
CONSENT FORM FOR PARTICIPANTS 
 
 
I have read the Information Sheet concerning this project and understand what it is about. 
All my questions have been answered to my satisfaction. I understand that I am free to 
request further information at any stage. 
I know that: 
1. My participation in the project is entirely voluntary; 
2. I am free to withdraw from the project at any time without any disadvantage; 
3. Personal identifying information will be destroyed at the conclusion of the project but any raw 
data on which the results of the project depend will be retained in secure storage for ten years; 
4. I will be given free instructions on oral hygiene, free toothbrushes, toothpastes and lozenges 
during the study; 
5. I understand that I will take two tablets a day for one month 
6. The researchers will write up the results from this study for their University work. The results 
may also be written up in journals and talked about at conferences. My name will not be on 
anything the researchers write up about this study. 
 











This study has been approved by the University of Otago Human Ethics Committee. If you have any concerns about the 
ethical conduct of the research you may contact the Committee through the Human Ethics Committee Administrator   
(ph 03 479 8256 or email gary.witte@otago.ac.nz). Any issues you raise will be treated in confidence and investigated 







Efficacy of the oral probiotic Streptococcus salivarius in managing 
biofilm formation in patients wearing fixed orthodontic appliances: 
A double-blind randomised placebo-controlled trial 
 
CONSENT FORM FOR CHILD PARTICIPANTS 
 
 
I have been told about this study and understand what it is about. All my questions have 
been answered in a way that makes sense. 
I know that: 
1. Participation in this study is voluntary, which means that I do not have to take part if I don’t 
want to and nothing will happen to me. 
2. I can stop taking part at any time and don’t have to give a reason. 
3. If I have any worries or if I have any other questions, I can talk to the researchers about them. 
4. Papers and computer files with my information will only be seen by the researchers and the 
people they are working with. They will keep whatever I say private. 
5. I will receive free toothbrushes and toothpastes at every orthodontic visit during the study, as 
thanks for helping out. 
6. I understand that I will take two tablets a day for one month 
7. The researchers will write up the results from this study for their University work. The results 
may also be written up in journals and talked about at conferences. My name will not be on 
anything the researchers write up about this study. 
 











This study has been approved by the University of Otago Human Ethics Committee. If you have any concerns about the 
ethical conduct of the research you may contact the Committee through the Human Ethics Committee Administrator  
(ph. 03 479 8256 or email gary.witte@otago.ac.nz). Any issues you raise will be treated in confidence and investigated 






Efficacy of the oral probiotic Streptococcus salivarius in managing 
biofilm formation in patients wearing fixed orthodontic appliances: 
A double-blind randomised placebo-controlled trial 
 
 
CONSENT FORM FOR PARENTS/GUARDIANS 
 
 
I have read the Information Sheet concerning this project and understand what it is about. 
All my questions have been answered to my satisfaction. I understand that I am free to 
request further information at any stage. 
I know that:- 
1. My child’s participation in the project is entirely voluntary; 
2. I am free to withdraw my child from the project at any time without any disadvantage; 
3. Personal identifying information will be destroyed at the conclusion of the project but any raw 
data on which the results of the project depend will be retained in secure storage for ten years; 
4. If I have any worries or if I have any other questions, then I can talk about these with the researchers. 
5. My child will receive free advice on oral hygiene, free toothbrushes and toothpastes during the 
study as thanks for taking part. 
5. I understand that my child will take two tablets a day for one month 
6. The researchers will write up the results from this study for their University work. The results 
may also be written up in journals and talked about at conferences. My child’s name will not be 
identified on anything the researchers write up about this study. 
 








(Name of child) 
 
This study has been approved by the University of Otago Human Ethics Committee. If you have any concerns about the ethical 
conduct of the research you may contact the Committee through the Human Ethics Committee Administrator (ph. 03 479 8256 or 

























  Sterile Blunt probe, mirror, tweezers,  triple-x 
 
  Vial for plaque 
 
  Plaque disclosing tablet 
 






































Thank you once again for agreeing to take part in this  study. 
 
Please use the toothbrushes and toothpastes provided by us. The lozenges don’t require any 
special storage instructions, maybe just keep them next to your toothbrush so it is easy to 
remember to take them. 
 
What to do: 
 
 




Brush your teethà Suck 1 lozenge à Record on chart 
 




The success of our study relies heavily on our participants, so if you have any problems 
please feel free to get in touch at benga221@otago.ac.nz or 0273052448. If you could  
please let us know if anything changes during the trial period (such as starting a course of 
antibiotics), that would be great! 
 
What else? 
We will send out text and email reminders to take the lozenges once in the morning and 
evening. We will also use this system to remind you about your next appointment. 
 
Thanks again and see you soon! 
Regards, 






Appendix 9. Lozenge reminder chart 
 
 
Please tick each time you take 
one of your lozenges. 
 
Please remember to: 
 
BRING THIS FORM TO 









 Morning Night 
Monday   
Tuesday   
Wednesday   
Thursday   
Friday   
Saturday   
Sunday   
   
Monday   
Tuesday   
Wednesday   
Thursday   
Friday   
Saturday   
Sunday   
   
Monday   
Tuesday   
Wednesday   
Thursday   
Friday   
Saturday   
Sunday   
   
Monday   
Tuesday   
Wednesday   
Thursday   
Friday   
Saturday   
Sunday   
   
Monday   
Tuesday   
Wednesday   
Thursday   
Friday   
Saturday   










Thank you for agreeing to take part in the BLIS  Study. 
 
 
You were initially selected because you are undergoing orthodontic treatment at the Dental 
School with Azza, Yana, Catherine or Gareth. You have opted in to the Study either via 
return mail, after receiving a phone call, or at your last orthodontic appointment with Azza, 
Yana, Catherine or Gareth. 
 
You should have already received all information documents outlining details of the study 
and been given appropriate consent forms to sign (if you have not, please email us at 
benga221@otago.ac.nz, so they can be sent to you). 
 
Please find below your appointments for the BLIS Study (and any orthodontic treatment 
appointments you already have scheduled in our appointment system). The BLIS Study 
appointments have been carefully allocated in 0 week, 4 week and 12 week intervals, 
starting the weeks of the 27th July, 24th August and 16th November. 
 
Each appointment will be 30 minutes long and we will try our very best to keep on time. If 
you could arrive 10 minutes before your appointment, that would be great! We have 
endeavoured to make these appointments as convenient for you as possible and have tried 
to balance them around your orthodontic treatment appointments the best we can. 
However, with over 200 appointments to schedule, it has not been an easy task, and we 
have unfortunately been left with very little wriggle room! Hopefully they are suitable. 
 
We are extremely grateful to you for giving up your time to be a part of this study-the first 
of its kind in the orthodontic world! Your attendance at all appointments will certainly 
determine its success, so if you have any questions that haven't yet been answered or if we 
can help in any way, please feel free to call or email us (benga221@otago.ac.nz or 
0273052448) . Otherwise, we look forward to seeing you at your first appointment. 
 
What will happen at appointment one? 
Firstly, Gareth will check that the informed consent form has been filled out, all inclusion 
criteria has been met and that you have no further questions. He will then take 3 breath 
measurements by having you breathe onto a straw. He will then take measurements of the 
plaque on your teeth and assess gum health. This will be followed by taking a sample of your 




the plaque that is on each tooth surface. You will then be asked to remove the plaque (that 
is shown by the dye) by brushing. Gareth will then give you mouthwash to rinse with and 
give you your first lozenge to suck on. You will suck a second lozenge at night time and 




Further instructions and information will be given at your first appointment. 
We will send out text and email reminders to take the lozenges once in the morning and 








If you can't make your appointments for any reason please contact us so we can try 
reschedule you. 
 
We really appreciate your involvement, thanks once again and see you soon! 
Regards, 
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Clinical Trial Procedure (Baseline Appointment) 
 
In dental chair, confirm consent form has been signed and patient satisfies all inclusion 
criteria and has no questions. If no problems, trial can begin. Fill out details at top of Data 
Recording Form. Give explanation on trial proceedings 
ê 
VSC recorded 3 times with Halimeter 
ê 
Plaque sampling 
Supra-gingival dental plaque collected from all teeth with an explorer, pooled and 
transferred to centrifuge tube 
ê 
Temporarily store samples in a bucket of ice (ice obtained from 1st floor of Theatre, or 3rd 
floor lab ice box), within 30 minutes of sampling. Samples will be then stored (-80oC) in the 








Plaque removed by patient (brushing teeth and tongue) 
ê 
Investigator ensures all plaque removed 
ê 
Patient to rinse for 30 seconds with 30ml antibacterial Mouth rinse 
ê 
Patient to suck first lozenge (remind patient to suck not chew) 
ê 





Clinical Trial Procedure (1-month Appointment) 
 
 
Compliance Assessment. Collect Sticker chart and collect and record remaining lozenges 
 
ê 




Supra-gingival dental plaque collected from all teeth with an explorer, pooled and 
transferred to centrifuge tube 
ê 
Temporarily store samples in a bucket of ice (ice obtained from 1st floor of Theatre, or 3rd 
floor lab ice box), within 30 minutes of sampling. Samples will be then stored (-80oC) in the 














Clinical Trial Procedure (4-month Appointment) 
 
 




Supra-gingival dental plaque collected from all teeth with an explorer, pooled and 
transferred to centrifuge tube 
ê 
Temporarily store samples in a bucket of ice (ice obtained from 1st floor of Theatre, or 3rd 
floor lab ice box), within 30 minutes of sampling. Samples will be then stored (-80oC) in the 




















Plaque sampling (blunt explorer)  
 
ê 





Put vial on ice in clinic until able to go to lab 
 
ê 
Store in -800C until 








II. DNA purification from samples 1a-65a, T=0 
 
 
PureLink Genomic DNA kit-Gram Positive Protocol 
 
 
Step I-Lysis (production of Gram Positive Bacterial Cell Lysate) 
 
 
Set two water baths at 370C and 550C, respectively 
ê 
Defrost samples at room temperature 
ê 
Dissolve 200 mg of lysozyme in 1 mL of Digestion Buffer (this gives a stock solution of 200 
mg/mL). Add 50 µl of this stock solution to the microcentrifuge containing the sample (this 
gives a final lysozyme concentration of 10 mg/ml). 
ê 
Add 20 µl of RNAse to the sample and mix 
ê 
Incubate at 370C for 30 minutes (mix every 10 minutes by tube inversion) 
ê 
Add 20 µl of proteinase K. Mix well by brief vortex 
ê 
Add 500 µl PureLink Genomic Lysis/Binding Buffer and mix well by brief vortex 
ê 
Incubate at 550C for 30 minutes – no need to invert but swirl every 10 minutes 
ê 
Add 500 µl of 100% ethanol and mix well by vortex for 5 seconds to yield a homogenous 
solution 
ê 







Transfer first 500 µl of Lysate sample to a Purelink Genomic Spin Column that is positioned 
in a 2-ml collection tube 
ê 
Centrifuge at 10,000-x g for 60 seconds 
ê 
Discard the 2-ml collection tube containing flow through and place the column in a new 2- 
ml collection tube 
ê 
Transfer second 500 µl of Lysate sample to the Purelink Genomic Spin Column 
ê 
Centrifuge at 10,000-x g for 60 seconds 
ê 
Discard the 2-ml collection tube containing flow through and place the column in a new 2- 
ml collection tube 
ê 
Transfer final third 500 µl of Lysate sample to the Purelink Genomic Spin Column 
ê 
Centrifuge at 10,000-x g for 60 seconds 
ê 
Discard the 2-ml collection tube containing flow through and place the column in a new 2- 






Step III-Washing DNA 
 
 
Add 500 µl of Wash buffer 1 (with added ethanol) to the Purelink column and centrifuge at 
10,000-x g for 60 seconds 
ê 
Discard the flow through that presents in the collection tube. Place the Purelink column 
back into the 2-ml collection tube 
ê 
Add 500 µl of Wash Buffer 2 (prepared with Ethanol) to the Purelink column and centrifuge 
at 10,000 x g for 60 seconds. Repeat this step. 
ê 
Discard the flow through that presents in the collection tube. Place the Purelink column 
back into the 2-ml collection tube and centrifuge again for 3 minutes at maximum speed (14- 
16,000 x g) to dry the column matrix. Discard the collection tube. 
ê 






Step IV- Eluting DNA 
 
 
Transfer the dried Purelink column to a sterile 1.5-ml centrifuge tube (use sterile swabs to 
remove excess ethanol) 
ê 
Add 70 µl of PureLink Genomic Elution Buffer to the centre of the column matrix 
ê 
Leave it for 15 minutes at room temperature 
ê 
Centrifuge at maximum speed for 1 minute to elute the purified DNA 
ê 




IIb. DNA purification from samples 1b-65b, T=1 
 
 
PureLink Genomic DNA kit 
 
 
Step I-Lysis (production of Gram Positive Bacterial Cell Lysate) 
 
 
Set two water baths at 370C and 550C, respectively 
ê 
Defrost samples at room temperature 
ê 
Dissolve 200 mg of lysozyme in 1 mL of Digestion Buffer 
(this gives a stock solution of 200 mg/mL). 
ê 
Centrifuge tubes containing samples at maximum speed for 1 min to harvest the bacterial 
cells 
ê 
Aspirate off digestion buffer, leave pellet completely submerged 
ê 
Re-suspend pellet in 100 µl of Lysozyme Digestion Buffer containing Lysozyme from Step 2. 
This gives a final lysozyme concentration of 20 mg/ml. 
ê 
Incubate at 370C for 30 minutes (every 10 minutes invert) 
ê 
Add 20 µl of proteinase K. Mix well by brief vortex 
ê 
Add 200 µl PureLink Genomic Lysis/Binding Buffer and mix well by brief vortex 
ê 
Incubate at 550C for 30 minutes – no need to invert but swirl every 10 mins 
ê 
Add 200 µl of 100% Ethanol and mix well by vortex for 5 seconds to yield a homogenous 
solution 
ê 







Transfer all Lysate sample (~500 µl) to a Purelink Genomic Spin Column 
that is positioned in a 2ml collection tube 
ê 
Centrifuge at 10,000-x g for 60 seconds 
ê 
Discard the 2-ml collection tube containing flow through 






Step III-Washing DNA 
 
 
Add 200 µl of Wash buffer 1 (prepared with ethanol) to the purelink column 
and centrifuge at 10,000-x g for 60 seconds 
ê 
Discard the flow through that presents in the collection tube. Place the Purelink column 
back into the 2ml collection tube  
 
ê 
Add 200 µl of Wash Buffer 2 (prepared with Ethanol) to the 
purelink column and centrifuge at 10,000-x g for 60 seconds. 
Repeat this step. 
ê 
Discard the flow through that presents in the collection tube. 
Place the Purelink column back into the 2ml collection tube 
and centrifuge again for 3 minutes at maximum speed (14-16,000xg) 
to dry the column matrix. Discard the collection tube. 
 
ê 




Step IV- Eluting DNA 
 
 
Transfer the dried purelink column to a sterile 1.5-ml centrifuge tube 
(use sterile swabs to remove excess Ethanol) 
ê 
Add 70µl of PureLink Genomic Elution Buffer to the centre of the column matrix 
 
ê 
Leave it for 15 minutes at room temperature 
 
ê 
Centrifuge at maximum speed for 1 minute to elute the purified DNA 
 
ê 




III. PCR Quantification – NanoVue Spectrometer 
 
 
Clean NanoVue spectrophotometer with distilled H20 and Kimwipes 
 
ê 
Add 2 µl of elution buffer (twice) to the spectrometer machine for calibration 
 
ê 
Press OA/100% T to zero (to blank the detector) 
 
ê 
Remove elution buffer 
 
ê 
Add another 2 µl of elution buffer and machine will automatically do the second reading 
 
ê 
Remove elution buffer 
 
ê 
Vortex sample centrifuge tube. Add 2 µl of sample 
 
ê 




IV. Preparing master mix for PCR 
 
 
T=0 monthà 18 samples + 1 negative= 19 reactions 
T=1 monthà 18 samples + 1 negative= 19 reactions 










Ready to load (40 reactions) 
Buffer 2.5 µl 100 µl 
Primer 1 (forward) 0.5 µl 1 µl 
Primer 2(Reverse) 0.5 µl 1 µl 
dNTP mix 0.5 µl 20 µl 
MgSo4 2 µl 80 µl 
Taq enzyme 0.25 µl 10 µl 
Water 17.75µl 710 µl 
Genomic DNA 1 µl  









Place the tubes in the wells 
ê 
Set programme to Unnamed C 
ê 






V. Running a gel 
 
 
Making a gel 
 
 
Mix 0.80 grams of Agarose and 80 ml of 1 x TAE buffer and boil in a microwave overn until 
all agarose has melted 
ê 
Cool to room temperature (5 minutes) 
ê 
Pour into a gel tray and leave it to set 
ê 
Once gel is set, remove comb and place inside a gel electrophoresis tank 
containing 1 x TAE buffer 
ê 
Mix 5 µl of PCR product with 1 µl of 6X loading dye 
and dispense into allocated wells in the gel. Load 5 µl of 1 kb DNA ladder 
ê 
Run gel at 100 volts for approximately 90 minutes 






The samples, each containing at least 20 ng of purified genomic DNA at a concentration of 
at least 5 ng/µl, were placed in ABI Fast 96-well real-time PCR plates, with seals, and 
packaged in dry ice. The 130 purified and quantified samples of genomic DNA templates 
were then sent to New Zealand Genomics Limited (NZGL) for sequencing. However, since 
NZGL had the 16S V3 - V4 rRNA primers to amplify and generate the libraries for the 




Appendix 14. Laboratory tasks undertaken by our team prior to sample delivery to 
NZGL for sequencing 
 
 
Laboratory tasks undertaken by our team-mock samples 
A preliminary PCR experiment with the QC primers (V3-V4) was performed as specified by 
NZGL. 
The first three lanes contained three different oral samples. The fourth lane contained 
digestion buffer only, to act as the non-oral, negative control sample. The fifth lane was a 
PCR without template DNA (water only), and the final lane was a DNA marker. The 
template DNA used was at concentrations of 12-15 ng/ul, and one microlitre (12-15 ng) was 
used in each PCR. 
The preliminary results showed considerable amounts of bacterial DNA in the oral 
samples but also a lot of contaminating human DNA, as indicated by extra bands (“ladder”) 
on the PCR gel. These unfortunate results were similar to a previous project undertaken by 
some of the research team in the past. 
These results may have rendered certain sequences useless as the contaminating human 
DNA could dramatically reduce the bacteria-specific sequences. 
Consequently an attempt was made to optimise the conditions for the subsequent PCR 
with the 130 samples. Polymerisation times were changed from 35 seconds to 10 seconds. 
Annealing temperatures were changed from 53oC to 55-60oC. Although the unfavourable 
results could also have been due to the enzyme used, this was unlikely. 
The team also performed trial purifications of pure bacterial cultures with existing 
columns to be familiar with procedures and ensure systems were optimised before 
proceeding with the 130 oral samples. The trial purification included quantification and gel 
electrophoresis for template quality control. The trial oral genomic DNA procedures 
worked very well which ensured the preparation of the 130 samples would be suitable for 
NZGL, however they were informed of the concern regarding the initial sample 
contamination and appropriate guidance was obtained. 
 
Laboratory  tasks-actual samples 
The 128 human mouth-swab samples were extracted and purified (half placebo, half 
probiotic), as well as two controls, giving a total of 130 samples. 




They were long primers with most of the primer being the Illumina recognition sequence: 
• V3-Fwd   





At least 20 ng of purified genomic DNA was provided for each sample at a concentration of 
at least 5 ng/ul using the ‘Purelink’ extraction kit from Life-Technologies. 
The quality of the genomic DNA was quantitated and assessed, by carrying out 
NanoVue analyses and by running a small portion of samples on a 2% agarose gel with a high 
molecular weight ladder. A preliminary gel image of a small portion of ‘good’ and ‘bad’ 
sample PCR products generated using the V3-V4 primers and their corresponding NanoVue 
readings, were sent to NZGL. NZGL were to ensure that the genomic DNA samples were 
of high molecular weight, of good quantity and quality prior to the full set of samples being 
sent for sequencing. 
 
 
Sample quantity and quality-Gel images and data from NanoVue 
 
 
The gel image appeared to show some non-specific binding as indicated by a faint higher 
molecular weight band, but changes that were made to the cycling protocol, following the 
preliminary experiments, reduced the concentration of the unwanted products significantly. 
It is known that high quality genomic DNA should run as a high molecular weight band on a 




lower molecular weight smearing. It is suggested that if the majority of the DNA is below 10 
kb or smearing is visible, this suggests that the DNA is degraded or indicative of the 
presence of RNA contamination, which could influence the success of sequencing results. 
The Massey Genome Service uses tailed PCR primers which flank the 16S V3-V4 rRNA 
hypervariable region to generate the libraries for their projects. Therefore, it was ensured 
that the products sent (i.e. the stronger ~500-bp bands on the gel) contained the 16S V3-v4 
rRNA hypervariable region by confirming with NZGL the PCR primer sequences that we 
used to generate these amplicon products before delivering the samples to their facility. 
Regarding the OD 260/280 readings. There were some samples where the reads were 
low (below 1.8), which could indicate the samples had some protein or other organic 
contaminants present. However, NZGL believed that so long as they could get amplified 
PCR products off these samples then the quality should be adequate. 
NZGL checked our sequences against their 16S V3-V4 target sequences as a final check 
to make sure the ~500-bp products actually represented this region. They confirmed that 
these products were indeed amplified 16S V3-V4 regions and proceeded with the 
sequencing phase. 
Samples were prepared in two separate plates, each containing 65 samples (including a 
template-free water [negative] control) for each Illumina MiSeq sequencing run. Each plate 
represented the timeline when the samples were collected: Baseline (T=0) and 1-month 
following lozenge use (T=1). Template Genomic DNA samples were sent to NZGL in dry 
ice via overnight courier, for library preparation and MiSeq sequencing. 
 
Work by NZGL-Illumina MiSeq/16s V3-V4 amplicon sequencing 
New Zealand Genomic Laboratories (NZGL) was contracted to generate 16S rRNA 
amplicon libraries, containing a set of core genes, using an Illumina 16S V3-V4 metagenomics 
protocol or custom amplicon single-step PCR. The overall aim was to produce a microbial 
diversity survey whereby we were provided with genomic and bioinformatics deliverables. 
 
Library  Preparation method 
The 130 libraries (baseline and 1-month samples including two controls) were prepared 
using the Illumina 16S V3-V4 rRNA library preparation method split into two batches of 65 
samples for each Illumina MiSeq run. The Massey Genome Service had dual index PCR 




PCR Library preparation method” to prepare the libraries. The libraries were pooled by 
equal molarity before being loaded onto the Illumina MiSeq runs. 
 
Two Illumina MiSeq 2X 250 base PE runs 
The 130 libraries were run on two Illumina MiSeq 2X 250 base PE runs, version  2 
chemistry, ~ 65 libraries for each run. These two runs generated approximately 19.2-24 
million reads, ~147,692–184,615 reads per sample and 9.6-12.0 Gb of total data output. It 
was noted that the sequencing data output estimation included the 20% PhiX loaded as an 
internal sequencing control. 
 
Genomic tasks 
• Sample QC check 130 genomic DNA samples 
• Library preparation of 130 samples (custom single-step PCR library preparation method) 
• Library QC check 130 amplicons libraries 
• Two Illumina MiSeq 2X 250 base PE runs 
• Data QC check of two Illumina MiSeq runs 
• Data delivery via BIO-IT 
 
 
Genomics  deliverables 
3 data outputs: 
• Unprocessed data: Demultiplexed fastq sequence reads 
• Processed data: PhiX control library reads and adapter sequences removed, using 
FASTQ-MCF1 
• Processed_Trimmed data: sequence reads from “Processed data” trimmed at an 
error probability of 0.01 (Phred score of Q20) 
All data generated was QC checked using the following processes: 
• FastQC and FastQscreen 
• SolexaQA2 
• Map back to the PhiX control library to identify the known SNPs, with BWA, samtools 
and Varscan. This QC data, along with a “Data Quality Report”, “Sequencing Run Report” 






The NZGL bioinformatics team was instructed to complete a number of tasks. The overall 
intention was to perform an analysis of the generated 16S rRNA reads. This was done 
through the use of mothur, QIIME or similar programs and/or environment to provide a 
phylogenetic profile of the organisms present in the sample in a tabulated form for further 
analysis by our team. 
 
1. For each sample: 
a. Detailed quality assessment at various error probabilities. 
b. Assessment of overlapping using tools such as Flash to maximise the output. 
 
2. For all samples, the following work was performed in QIIME: 
a. Processing of the reads to generate an index file required for QIIME analysis. 
b. The protocols supplied with QIIME were followed to generate a taxonomic overview of 
the samples. 
c. Taxonomic profiles of the individual samples were compared using functions in QIIME to 
look for similarities and differences between samples via a variety of output methodologies. 
 
3. A pair of reports on the work carried out: 
a. An interim report on the first batch of data. 
b. A final report covering the analysis of the second batch, a comparison with the first batch. 
 
Bioinformatics  deliverables 
• Data processed at a variety of quality thresholds and subsequently analysed with Flash. 
• Metafiles and associated files for working with the QIIME workflow. 
• Summary data from the QIIME pipeline mostly viewable as html files in a web browser. 
• Other summary outputs from other programs as other ways to visualise the data results. 
• Two reports (one interim and one final) summarising the work performed. 
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Appendix 15. Clinical examination details 
 
 
PI and GI 
The plaque index, gingival index and volatile sulphur compound levels of the participants 
were recorded by researcher G.B, a dentist, at baseline, 1-month and 4-month time 
intervals. 
We used an adaptation of the modified Silness and Löe Plaque Index as described by 
Clerehugh et al., to measure the amount of biofilm formation (Clerehugh et al., 1998) The 
teeth were divided into mesial, distal, gingival, and incisal (occlusal) regions in relation to the 
bracket. Plaque was then scored for each of the four areas based on four plaque index 
codes (Table 4.1) as used by Löe (Löe, 1967). 
The four values were averaged for each tooth to give a mean PI tooth score. An overall 
final mean PI for all involved teeth was calculated for each participant. The plaque index 
measurement involved recording soft and hard deposits on all teeth including and mesial to 
the first molars in both arches. 
Diagram showing the modified Silness and Löe index as described by 
Clerehugh and colleagues. The tooth is divided into mesial (M), distal (D), 
gingival (G), and incisal/occlusal (I) regions for plaque measurement. 
 
Table 4.1: Plaque Index four code scoring system of Löe (Löe, 1967) 
 
Score Criteria 
0 No plaque. 
1 A film of plaque adhering to the free gingival margin and adjacent area of the tooth. The 
plaque may be seen in situ only after application of disclosing solution or by using the 
probe on the tooth surface. 
2 Moderate accumulation of soft deposits within the gingival pocket, or the tooth and  
gingival margin which can be seen with the naked eye. 
3 Abundance of soft matter within the gingival pocket and/or on the tooth and gingival 
margin. 
 
GI measurements were made with a blunt probe. The same teeth as recorded in the plaque 
index were used. Four areas around each tooth (mesial (labial/buccal), distal (labial/buccal), 
labial/buccal and lingual/palatal) were scored based on four gingival index codes (Table 4.2), 
as used by Löe (Löe, 1967). A tooth GI mean and a participant GI mean was calculated as 




Table 4.2: Gingival Index System (Löe, 1967) 
 
Score Criteria 
0 No inflammation. 
1 Mild inflammation, slight change in colour, slight oedema, no bleeding on probing. 
2 Moderate inflammation, moderate glazing, redness, bleeding on probing. 




Levels of volatile sulphur compounds (VSCs) were assessed with patient’s breath samples 
using a Halimeter (Interscan Corp., Chatsworth, USA) based on the average of three 
readings. This was done in a standardized manner and in compliance with the manufacturers 
instructions, for best consistency of results. 
At the baseline appointment, following the clinical data collection, participants were 
asked to chew a plaque-disclosing tablet (Disclotabs, Colgate®) and then thoroughly remove 
the disclosed dental biofilm in their mouths by brushing with a new toothbrush (Colgate® 
Ortho, Colgate-Palmolive) and toothpaste (Colgate® Cavity Protection Toothpaste, 
Colgate-Palmolive) under the supervision of the principal investigator (G.B.). The 
participants then rinsed their mouths with water and a 30ml cup of Chlorehexidine 
mouthwash (Savacol®, Colgate®). They were then asked to suck the appropriate lozenge. A 
take home pack of the appropriate lozenges, toothpaste, toothbrush, compliance lozenge 
reminder chart, pen and further instructions were given for home use. The protocol 
required the participants to suck two lozenges each day, one after brushing the teeth in the 
morning and one after brushing the teeth at night. 
Each participant provided at least one email address and mobile telephone number 
where morning and night email and text message reminders were sent to enhance 
compliance with taking the lozenges. 
At 1 month, clinical data was collected in a similar manner. In addition, all remaining 
lozenges and lozenge reminder charts were collected for the analysis of compliance with 
lozenge consumption. At 4 months, clinical data was collected as in the previous two 
occasions (see Appendix 13) for further information on our clinical protocol). 
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